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INTRODUCTION 
 Polycystic ovarian syndrome (PCOS) is a multisystem endocrinopathy in 
women of reproductive age with the ovarian expression of various metabolic 
disturbances and a wide spectrum of clinical features like infertility, obesity, 
menstrual abnormalities and hyperandrogenism. The condition is relatively 
common and affects about 20% of women of reproductive years. The diverse 
manifestations of PCOS start at an early age when a girl is maturing into a young 
woman. 
 PCOS is characterized by chronic anovulation, oligomenorhea or 
amenorrhea, hyperandrogenism and polycystic ovary morphology on pelvic 
ultrasound. The condition is a diagnosis of exclusion and has been a topic of 
debate and many definitions have evolved over years.  
Patients are diagnosed to have PCOS according to Rotterdams 
ESHRE/ASRM- sponsored PCOS Consensus Workshop Group(2 out of 3 
must be present)a) Oligoovulation or anovulation b). Clinical or biochemical 
signs of hyperandrogenism c)Polycystic  appearance on ultrasonography in 
atleast one ovary and exclusion of other etiologies(congenital adrenal 
hyperplasia, androgen-secreting tumours, Cushing’s syndrome. 
Globally, the prevalence of PCOS ranges from 2.2% to 26%. Women with 
PCOS are also at higher risk for Insulin resistance, Type 2 diabetes mellitus, 
Obesity, Dyslipidemia, Hypertension, atherosclerotic cardiovascular disease, 
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Endometrial, hyperplasia and endometrial cancer, Obstructive sleep apnoea and  
mood disorders. 
The term ‘Metabolic Syndrome’ (syndrome X, insulin resistance 
syndrome) is widely used in clinical practice and research, consisting of a 
constellation of multiple interrelated risk factors of metabolic origin, which 
arises due to underlying insulin  resistance, which in turn  promotes the 
development of atherosclerotic cardiovascular vascular disease. The major 
features of the metabolic syndrome include central obesity, 
hypertriglyceridemia, low levels of high-density lipoprotein (HDL) 
cholesterol, hyperglycemia and hypertension.  
There are various emerging definitions for metabolic syndrome. It is defined 
according  to the modified American Heart Association/National Heart Lung 
Blood Institute AHA/NHLBI (ATP III 2005) definition. The main changes in 
this definition include (i) defining the ethnic-specific difference in central 
obesity by using the World Health Organization recommendation for waist 
circumference ≥80 cm in Asian women, and (ii) and reducing the threshold for 
impaired fasting glucose to 100 mg% in accordance with the American Diabetes 
Association revised definition. 
The International Diabetes Federation (IDF) has introduced a new 
definition, combining both clinical and research needs with a slight modification 
in the ATP-III definition in 2005 where presence of abdominal obesity was 
considered mandatory for Metabolic Syndrome diagnosis. 
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About 25 % of the world’s population have metabolic syndrome. They 
are twice as likely to die from and three times as likely to have a heart attack or 
stroke when compared to people without the syndrome.  People with metabolic 
syndrome have a fivefold greater risk of developing type 2 diabetes(12). 
Prevalence of obesity and diabetes mellitus is India is also on the rise owing 
to urbanization and change in lifestyle. The prevalence of  metabolic syndrome 
in South Asians varies with region, extent of urbanization, lifestyle patterns, and 
socioeconomic and cultural factors. Recent data shows that about one-third of 
the urban population in large cities in India have the metabolic syndrome.  
PCOS is one of the major risk factor for metabolic syndrome and the 
prevalence of metabolic syndrome in PCOS is 40-50%(10). Since insulin 
resistance has its metabolic effect both on adolescent and adults, PCOS forms a 
key for search of metabolic syndrome. 
 The aim of our study is to find out the prevalence of metabolic syndrome 
using the IDF criteria in women with PCOS reproductive age group so that 
appropriate life style modifications, pharmacological and non pharmacological 
intervention would help in combating and preventing  the major deadly 
cardiovascular diasease, stroke etc.  Due to higher risk of metabolic syndrome in 
our ethnic population more stringent criteria of metabolic syndrome defined by 
the International Diabetes Federation (IDF) is used in our study. 
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AIM OF THE STUDY 
 To study the prevalence of metabolic syndrome in women with 
polycystic ovarian syndrome attending a tertiary care hospital using the 
new IDF criteria. 
 To study the pattern of metabolic syndrome components in women with 
polycystic ovarian syndrome. 
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REVIEW OF LITERATURE 
By far the most common, although the least understood,  cause of androgen 
excess is polycystic ovary syndrome (PCOS), accounting for a vast majority of patients 
seen. PCOS was  first described by Irving F. Stein and Micahel L. Leventhal as  a 
symptom complex associated with anovulation. Hence, Polycystic ovarian syndrome 
is also known as Stein–Leventhal syndrome . The earliest published description of a 
person with PCOS was in 1721 in Italy. 
 
PCOS affects 4–6% of women. The highest reported prevalence of PCO has 
been 52%among South Asian immigrants in Britain, of whom 49.1% had menstrual 
irregularity Approximately 75% of anovulatory women of any cause have polycystic 
ovaries. Ultrasonographic findings of polycystic ovaries are found in 8-25% of normal 
women. 14% women on oral contraceptives are found to have polycystic ovaries.  
 
THE CAUSE OF PCOS 
The characteristic polycystic ovary emerges when a state of anovulation  
persists for any length of time. Whether diagnosis is by ultrasound or by the 
traditional clinical and biochemical criteria, a cross section of anovulatory women at 
any point of time will reveal that approximately 75% will have polycystic ovaries.   
As there are many causes of anovulation, there are many causes of polycystic 
ovaries. A similar clinical picture and ovarian condition can reflect any of the condition 
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like adrenal hyperplasia, Cushing’s  syndrome, hyperprolactinemia, and androgen 
producing tumours. 
“It is said that normally ovulating women with polycystic ovaries on 
ultrasonography have underlying metabolic abnormalities. Most of the women with 
polycystic ovaries on ultrasonography are clinically and endocrinologically normal”(8). 
 
DIAGNOSIS OF PCOS   
Since there are so many clinical and biochemical features in PCOS, the exact 
definition of PCOS is perplexing. At a recent joint  ‘European Society of Human 
Reproduction and Embryology/American Society for Reproductive Medicine 
(ESHRE/ASRM)’ consenses meeting (Rotterdam criteria), a refined definition of 
PCOS was agreed—(presence of two out of the following three criteria): 
1. Oligomenorrhoea and/or anovulation 
2. Hyperandrogenism (clinical and/or biochemical) 
3. Polycystic ovaries, with the exclusion of other aetiologies 
 
Pathophysiology  
The hyperandrogenism and anovulation that accompany PCOS is caused by 
abnormalities in four endocrinologically active compartments, (1) the ovaries (2) the 
adrenal glands (3) the periphery (fat) and (4) the hypothalamic-pituitary compartment. 
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PATHOPHYSIOLOGY OF PCOS 
1)Hyperandrogenicity 
 
   2) Anovulation 
 
 
 
3) Hypothalamic-pituitary compartment in PCOS 
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4)Obesity and insulin resistance 
 
 
SHBG, sex hormone binding globulin; IGFBP, Insulin-like growth factor binding 
protein. 
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Ovarian compartment 
In patients with PCOS, the ovarian compartment is the most consistent 
contributor of androgens. Dysregulation of CYP17, the androgen-forming enzyme in 
both the adrenals and the ovaries, may be one of the central pathogenetic mechanisms 
underlying hyperandrogenism in PCOS. The ovarian stroma, theca, and granulosa 
contribute to ovarian hyperandrogenism and are stimulated by LH. This hormone 
relates to ovarian androgenic activity in PCOS in a number of ways and they are: 
 
1. Total and free testosterone levels correlate directly with LH levels 
2. The ovaries are more sensitive to gonadotropic stimulation, possibly as a result 
of CYP17 dysregulation 
3. Treatment with a gonadotrophin-releasing hormone (GnRH) agonist effectively 
suppresses serum testosterone and androstenedione levels 
4. Larger doses of a GnRH agonist are required for androgen suppression than for 
oestrogen suppression(9). 
 
The increased testosterone levels in patients with PCOS are considered ovarian 
in origin. The serum total testosterone levels are usually no more than twice the upper 
normal range (20–80 ng/dL). However, in ovarian hyperthecosis, the values may 
reach 200 ng/dL or more. High intraovarian androgen concentrations inhibit 
follicular maturation(8). Although ovarian theca cells are hyperactive, the retarded 
follicular maturation results in inactive granulosa cells with minimal aromatase activity 
for conversion to oestrogens. 
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Adrenal compartment 
The adrenal compartment also plays a role in the development of PCOS. 
Although the hyperfunctioning CYP17 androgen-forming enzyme coexists in both the 
ovaries and the adrenal glands, DHEAS is increased in only about 50% of patients 
with PCOS. The hyper-responsiveness of DHEAS to stimulation with ACTH, the 
onset of symptoms around puberty, and the observation that 17, 20-lyase activation 
(one of the two CYP17 enzymes) is a key event in adrenarche have led to the concept 
of  PCOS as an exaggerated adrenarche. 
 
Peripheral compartment 
The peripheral compartment, defined as the skin and the adipose tissue, 
manifests its contribution to the development of PCOS in several ways. 
“1. The presence and activity of 5α-reductase in the skin largely determines the 
presence or absence of hirsutism  
2. Aromatase and 17β-hydroxysteroid dehydrogenase activities are increased in fat 
cells, and peripheral aromatisation is increased with body weight 
3. The metabolism of oestrogens, by way of reduced 2-hydroxylation and 17α-
oxidation, is decreased”(9).  
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Hypothalamic-pituitary compartment  
“The hypothalamic-pituitary compartment also participates in aspects critical to the 
development of PCOS. 
1.  An increase in LH pulse frequency is the result of increased GnRH  pulse 
frequency. 
2. This increase in LH pulse frequency typically results in elevated LH and LH-to-
FSH ratio. 
3. FSH is not increased with LH, probably because of the synergistic negative 
feedback of chronically elevated oestrogen levels and normal follicular inhibin(9). 
 
About 25% of patients with PCOS exhibit elevated prolactin levels. The 
hyperprolactinaemia may result from abnormal oestrogen feedback to the 
pituitary gland. In some patients with PCOS, bromocriptine has reduced LH levels 
and restored ovulatory function. 
 
Genetic Considerations 
The familial clustering of anovulation and polycystic ovaries suggests an 
underlying genetic basis. At least one group of patients with this condition has been 
described inheriting the disorder, possibly by means of an X-linked dominant 
transmission. Studies of large families suggested inheritance in an autosomal 
dominant fashion, with premature balding as the phenotype in males(1).  
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P450c17 Dysregulation 
 The ovarian hyperandrogenic state of PCOS occurs as consequence  of an 
enzymatic dysregulation, specifically of P450c 17, the enzyme responsible for both 17 
α- hydroxylase and 17,20-lyase enzymes activities. Abnormal hyperactivity of this 
enzyme would account for the altered steroidogenesis in both the adrenal glands and 
the ovaries. It is difficult, if not impossible , to perceive if the abnormal enzyme activity 
occurs first or is a reflection of the anovulatory dysfunction state.  
The polycystic ovary is a consequence of the loss of ovulation and the 
achievement of the steady state of persistent anovulation 
  
1. There is a doubling of surface area ( volume increase is 2.8 times). 
2. The same number of primordial follicles is present, but the number of growing and 
atretic follicles is doubled. Each ovary may contain 20–100 cystic follicles. 
3. The thickness of the tunica is increased by 50%. 
4. A one-third increase in cortical stromal thickness and a 5-fold increase in 
subcortical stroma. 
5. There are 4 times more ovarian hilus cell nests (hyperplasia) (8).” 
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FUNCTIONAL DERANGEMENT -TWO CELL EXPLANATION 
 
“The functional problem can be understood in terms of the two-cell explanation 
of steroidogenesis. The follicles are unable to successfully change their micro-
environment from androgen dominance to estrogen dominance, the change that 
is essential for continued follicular growth and development(7). Measurement of the 
insulin-like growth factor binding proteins (IGFBPs) in follicular fluid reveals that the 
profile in polycystic ovaries is the same as that found in atretic follicles, higher levels 
of IGFBP-2 and -4. This is consistent with limitation of IGF-I and IGF-II activity, 
reducing the expression of aromatase action and allowing androgenic dominance in the 
microenvironment.  
 
However, there is a striking difference comparing polycystic granulosa cells 
with granulosa cells from atretic follicles. Granulosa cells from polycystic ovaries 
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are very sensitive to FSH; granulosa cells from atretic follicles are not.  Thus, the 
granulosa cells from the follicles in polycystic ovaries are not apoptotic (atretic), 
but simply arrested in development, and capable of responding to FSH stimulation(12).  
 
The functional picture that emerges (arrested granulosa cells and very active 
theca cells) corresponds to the morphologic histology of underdeveloped granulosa 
and hyperplastic and luteinized theca. Granulosa cells obtained from the small follicles 
of polycystic ovaries produce negligible amounts of estradiol but show a dramatic 
increase in estrogen production when FSH or IGF-I is added and a synergistic action 
when FSH and IGF-I are added together. In terms of the two-cell explanation, this 
behavior is consistent with a blockage of FSH response (probably through various 
growth factors), not an intrinsic steroid synthesis enzyme defect. Successful treatment 
depends, therefore, on altering the ratio of FSH to androgens; either increasing 
FSH (with clomiphene) or decreasing androgens (wedge resection) to overcome 
the androgen block at the granulosa level. This permits development of 
aromatization to bring about conversion of the microenvironment to estrogen 
dominance. Because anovulation with polycystic ovaries is a functional derangement, 
it is not surprising that these patients occasionally may ovulate spontaneously. Indeed, 
ovulation is unpredictable, and contraception may be necessary. 
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CLINICAL, BIOCHEMICAL, AND METABOLIC FEATURES OF PCOS 
Menstrual dysfunction typically occurs in PCOS, ranging from 
oligomenorrhoea to amenorrhoea. As a rule, patients with PCOS exhibit anovulation. 
Even in hyperandrogenic women with regular menstrual cycles, the rate of anovulation 
is about 20%.  Severe acne in the teenage years appears to be a common findings of 
PCOS.  
 
Obesity is found in over 50% of  patients with PCOS. The body fat is usually 
deposited centrally (android obesity), and a higher waist-to-hip ratio indicates an 
increased risk of diabetes mellitus and cardiovascular disease in later life. Insulin 
resistance and hyperinsulinaemia are commonly exhibited in PCOS. Insulin resistance 
is now recognised as a major risk factor for  the development of Type 2 diabetes 
mellitus. About one-third of obese PCOS patients have impaired glucose tolerance 
(IGT), and 7.5–10% have Type 2 diabetes mellitus(8).  
 
Abnormal lipoproteins are common in PCOS and include elevated total 
cholesterol, triglycerides, and low-density lipoproteins (LDL), and low levels of 
high-density lipoproteins (HDL) and apoprotein A-I(9). 
Other observations in women with PCOS include an increased incidence of 
hypertension over the years that reaches a 40% incidence by perimenopause, a greater 
prevalence of atherosclerosis and cardiovascular disease, and an estimated  sevenfold 
increased risk for myocardial infarction. 
 
21 
Approximately 70–80% of women with PCOS demonstrate frank elevations 
in circulating androgens, particularly free testosterone, and 25–50% will have 
elevated levels of the adrenal androgen metabolite, DHEAS(9). Prolactin levels are 
usually normal, although they may be slightly elevated generally < 40 ng/mL) in a 
small fraction of patients. 
 
Increased LH:FSH ratio 
The luteinising hormone/follicle-stimulating hormone (LH/FSH) ratio is greater 
than 2 or 3 to 1 in approximately 60% of these patients. The increase in LH pulse 
frequency and pituitary response GnRH are independent of obesity(10). Obesity 
attenuates the LH response to GnRH and LH pulse amplitude is relatively normal in 
overweight women with PCO, although the increase in pulse frequency is maintained. 
 
 The increased pituitary and hypothalamic sensitivity can be attributed to the 
increased oestrone levels, but an important contributing factor is the impact of the 50% 
reduction in SHBG concentration due to increased testosterone and in patients with 
hyperinsulinaemia, due to a direct insulin effect on the liver. 
 
When compared with levels found in normal women, patients with persistent 
anovulation have higher mean concentration of LH, but low or low normal levels 
of FSH. The elevated LH levels are partly due to increased sensitivity of the pituitary 
to releasing hormone stimulation, manifested by an increase in LH pulse amplitude 
and frequency but mainly amplitude(4). It is noteworthy that this high levels of LH 
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is characterised by an increased level of LH bioactivity. The high LH and low FSH can 
also be due to increased frequency of GnRH pulsatile secretion.  
 
Central opoid tone appears suppressed because there is no difference in response 
to naloxone. Indeed the enhanced pulsatile secretion of GnRH can be attributed to a 
reduction in hypothalamic opoid inhibition because of the chronic absence of 
progesterone. This is associated with increase in amplitude and frequency of LH 
secretion that is correlated with the levels of circulating oestrogen. It is likely that this 
increased activity is taking place at both hypothalamic and pituitary sites. This altered 
state is also associated with a change in the circadian patterns with the highest LH 
values occurring in late afternoon rather than at night(9). 
 
While not part of the diagnostic criterion, many women with PCOS appear to 
be uniquely insulin-resistant. Approximately 50–70% of patients with PCOS 
demonstrate profound insulin resistance and secondary hyperinsulinaemia, 
independent of body weight(8). In PCOS, insulin resistance usually refers to the 
impaired action of insulin in stimulating glucose transport and in inhibiting lipolysis in 
adipocytes. Insulin resistance in PCOS appears to be due to an intracellular defect of 
insulin signaling. The compensatory hyperinsulinaemia, resulting from the underlying 
insulin resistance, augments the stimulatory action of LH on the growth and androgen 
secretion of ovarian thecal cells, while inhibiting the hepatic production of SHBG. 
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Treatment of patients with PCOS with insulin sensitisers may result in lower 
circulating levels of LH suggesting that insulin resistance, or more likely 
hyperinsulinaemia, is in part responsible for the gonadotropic abnormalities observed 
in many women with PCOS. Since insulin is also a mitogenic hormone, the extremely 
elevated insulin levels may lead to hyperplasia of the basal layers of the epidermis, 
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resulting in the development of acanthosis nigricans (a velvety, hyperpigmented 
change of the crease areas of the skin), and acrochordons. Overall, insulin resistance 
and secondary hyperinsulinaemia affects a large fraction of patients with PCOS, and 
may cause or augment the androgen excess of these patients. 
 
THE VICIOUS CYCLE CAUSING ANOVULATION 
  
The increased LH secretion as expressed by the LH:FSH ratio is positively 
correlated with the increased free oestradiol(12). There is no evidence to support a 
role for inhibin suppression of FSH. In fact insulin production in granulosa cells is 
suppressed. A sensitive assay for inhibin B has however detected high levels in women 
with PCO suggesting that multiple small follicles can suppress FSH levels by 
increasing the circulating levels of inhibin B. 
 
Because the FSH levels are not totally depressed, new follicular growth is 
continuously stimulated, but not to the point of full maturation and ovulation, in 
the form of multiple follicular cysts 2–10 mm in diameter. These follicles are 
surrounded by hyperplastic theca cells, often luteinized in response to high LH levels. 
The accumulation of follicular tissue in various stages of development allows an 
increased and relatively constant production of steroids in response to 
gonadotrophic stimulation(10). This process is self sustaining.  As various follicles 
undergo atresia, they are immediately replaced by new follicles of similar limited 
growth potential.  
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The elevated androgen levels compound the problem through the process of 
extraglandular conversion as well as suppression of SHBG synthesis resulting in 
elevated oestrogen levels and associated increase in free testosterone. This prevents 
the normal follicular development and induce premature atresia(8). 
 There is allegedly an associated enzymatic dysregulation specifically of 
P450c17, the enzyme responsible for both 17 α hydroxylase and 17, 20 lyase activities. 
This may account for the altered steroidogenesis in both ovaries and adrenal glands. 
The intermediates from 17 hydroxypregnenolone and androstenedione hyper-respond, 
testosterone rises slightly yet significantly and oestrone and oestradiol marginally. The 
3β hydroxy intermediate pregnenolone, 17 hydroxyprogesterone and DHEA rise only 
slightly. This coupled with hyperresponsiveness of DHEAS to ACTH in the 
adrenals completes the background for formation of PCO(11). There is growing 
evidence that hyperinsulinaemia may stimulate P450c 17 enzyme resulting in hyper 
androgenism”. 
 
INSULIN AND THE MECHANISM OF ANOVULATION IN POLYCYSTIC 
OVARIAN SYNDROME 
“The characteristic feature of anovulation in PCOS is the arrest of growth of 
antral follicles after reaching a diameter between 5 mm and 8 mm(9). This may be 
caused by premature activation of LH-mediated terminal differentiation of granulosa 
cells and that hyperinsulinaemia makes an important contribution to this phenomenon. 
In the normal menstrual cycle, granulosa cells of the dominant follicle become 
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responsive to the LH in the midfollicle phase at a follicle diameter of 10 mm, whereas 
subsidiary follicles do not respond to LH. 
In the preovulatory phase of the cycle, LH maintains and enhances 
steroidogenesis but triggers terminal differentiation so that once the granulose layer of 
the dominant follicle is exposed to LH, the cells undergo only two more cell divisions 
before growth is arrested(10). Theoretically, premature activation of this LH-
dependent effect would result in premature arrest of growth and failure of ovulation as 
in PCOS. Specifically, LH-stimulated oestradiol and progesterone production in cells 
from follicles as small as 4 mm in diameter. In contrast in follicles from, both ovulatory 
PCO women and normal ovaries, only dominant follicles of 9.5 mm or greater 
responded to LH. 
 
“It is believed that the remarkable amplification of LH action by insulin 
makes a major combination to the arrest of follicle growth(9). Other endemic 
factors, notably hyper secretion of LH and ovarian androgens, may also have a role and 
an intrinsic disorder of folliculogenesis cannot be ruled out. Ultrasonographic 
examination: This may be a useful method for the early detection and subsequent 
follow-up of PCOS. Generally, ovarian size is increased. The most important 
ultrasonographic finding is a bilaterally increased number of microcysts measuring 
0.5–0.8 cm with generally more than five microcysts in each ovary. As the number 
of microcysts increases and the ovarian volume enlarges, clinical and endocrine 
abnormalities become more obvious, and the condition becomes more severe.  
 
27 
INSULIN RESISTANCE 
Insulin resistance is defined as a reduced glucose response to a given amount 
of insulin. Resistance to insulin-stimulated glucose uptake is a relatively common 
phenomenon, sometimes referred to as syndrome X. The majority of patients with 
noninsulin-dependent diabetes mellitus have peripheral insulin resistance, but not all 
women who are insulin resistant are hyperandrogenic(8). The state of chronic 
hyperinsulinemia represents a compensatory response to the target tissue problem. 
These relationships involve changes in plasma free fatty acid concentrations. If 
the insulin levels necessary to suppress free fatty acid levels cannot be achieved, then 
the increase in free fatty acids leads to increased hepatic glucose production and 
hyperglycemia. There are several mechanisms for the state of insulin resistance: 
peripheral target tissue resistance, decreased hepatic clearance, or increased 
pancreatic sensitivity.  
 
The euglycemic clamp technique establishes a steady state of hyperinsulinemia 
with a normal glucose level at which point the glucose infusion rate equals glucose 
utilization. Adding insulin will measure the glucose uptake rate (the more insulin 
required, the greater the peripheral resistance, also referred to as a measure of 
insulin sensitivity). Studies with this technique indicate that hyperandrogenic women 
with hyperinsulinemia have peripheral insulin resistance and, in addition, a reduction 
in the insulin clearance rate due to decreased hepatic insulin extraction.  
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MECHANISM OF INSULIN RESISTANCE IN PCOS 
In women with polycystic ovaries, the peripheral insulin resistance is due to a 
defect beyond activation of the receptor kinase, specifically leading to reduced 
tyrosine autophosphorylation of the insulin receptor(9). The phosphorylation of 
serine and threonine residues on the insulin receptor reduces signal transmission, and 
excessive serine phosphorylation  has been demonstrated as a possible post-receptor 
defect in these patients, changing signal transduction.  
 
Serine phosphorylation of the beta chain of the insulin receptor and at the 
same time of the adrenal and ovarian P450c17 enzyme (the origin or cause of serine 
phosphorylation is uncertain, but presumably it would have a genetic basis) would 
explain both the hyperinsulinemia and hyperandrogenism. Serine phosphorylation 
increases 17,20-lyase activity and androgen production)(9). 
Stated simply, serine instead of tyrosine phosphorylation is an “off” mechanism 
for glucose transport, but an “on” mechanism for P450c17enzyme activity. This change 
in phosphorylation would be consistent with no abnormality in the number of receptors 
or in receptor function; the impaired insulin signal for glucose transport would be due 
to a post-receptor problem. Indeed, structural defects in the insulin receptor cannot be 
identified.  
 
Of course, different patients with the same clinical presentation may have 
different reasons for the insulin resistance, a spectrum of etiologies with a common 
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clinical expression. The defect in insulin action is limited to glucose metabolism; 
other biologic actions of insulin are not impaired(8). 
INHERITED HYPERINSULINEMIA 
There are rare causes of hyperinsulinemia and hyperandrogenism that are 
congenital in origin. Peripheral insulin resistance associated with 
hyperandrogenism and acanthosis nigricans, known as “type A syndrome,” can be 
due to mutations of the insulin receptor gene, which leads to decreased numbers of 
insulin receptors in target tissues. Leprechaunism is a rare syndrome in young girls 
with a mutation in the insulin receptor gene and perhaps defects in growth factor 
receptors; it is associated with severe insulin resistance, polycystic ovaries, 
hyperandrogenism, and acanthosis nigricans(8). Another subgroup, type B 
syndrome, consists of patients with autoantibodies to insulin receptors.  
 
This leaves a large collection of women with neither reduced nor abnormal 
insulin receptors nor autoantibodies, the most common clinical entity encountered, 
anovulatory women with hyperandrogenism and hyperinsulinemia. Possible 
mechanisms for the hyperinsulinemia include functional problems in the insulin 
receptor (which could also be a consequence of insulin receptor gene mutations) and 
inhibitors, which can interfere with insulin-receptor function after binding.  
 
Thus, there are at least 3 categories for peripheral target tissue insulin resistance: 
decreased insulin receptor numbers, decreased insulin binding, and post receptor 
failures. 
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THE ROLE OF OBESITY CAUSING HYPERINSULINEMIA AND 
HYPERANDROGENISM IN PCOS- AUGMETATATION 
 
Overweight, anovulatory women with hyperandrogenism have a characteristic 
distribution of body fat known as android obesity. Android obesity is the result of fat 
deposited in the abdominal wall and visceral mesenteric locations. This fat is more 
sensitive to catecholamines, less sensitive to insulin, and more active metabolically.  
 
This fat distribution is associated with hyperinsulinemia, impaired glucose 
tolerance, diabetes mellitus, and an increase in androgen production rates resulting in 
decreased levels of sex hormone-binding globulin and increased levels of free 
testosterone and estradiol. 
 
Central body (android) obesity is associated with cardiovascular risk 
factors, including hypertension and unfavorable cholesterol-lipoprotein profiles. The 
waist:hip ratio is the variable most strongly and inversely associated with the level of 
HDL 2, the fraction of HDL-cholesterol most consistently linked with protection 
from cardiovascular disease. A waist:hip ratio greater than 0.85 indicates android 
fat distribution(8).  
 
The adverse impact of excess weight in adolescence can be explained by the fact 
that deposition of fat in adolescence is largely central in location. Weight loss in women 
with lower body obesity is mainly cosmetic, whereas loss of central body weight is 
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more important for general health because an improvement in cardiovascular risk is 
associated with loss of central body fat. 
 
Hyperinsulinemia and hyperandrogenism, however, are not confined to 
anovulatory women who are overweight. Combination of increased androgen 
secretion and insulin resistance has been reported in both obese and non obese 
anovulatory women. However, insulin levels are higher and LH, SHBG, and IGFBP-
1 levels are lower in obese women with polycystic ovaries compared to non obese 
women with polycystic ovaries.. 
 
 Hyperinsulinemia and hyperandrogenism are not explained, therefore, solely 
by obesity, and specifically, android obesity. However, the presence of obesity adds 
the insulin resistance and hyperinsulinemia associated with obesity to that which is 
specifically unique to the anovulatory, polycystic ovary state(8).  
 
Correlation between Hyperinsulinemia and  Hyperandrogenism 
 
Most of the evidence supports hyperinsulinemia as the primary factor, especially 
the experiments in which turning off the ovary with a GnRH agonist does not change 
the hyperinsulinemia or insulin resistance. This indicates that disordered insulin action 
precedes the increase in androgens.  
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Indeed, there are 6 reasons to believe that hyperinsulinism causes 
hyperandrogenism: 
1. The administration of insulin to women with polycystic ovaries increases 
circulating androgen levels.  
2. The administration of glucose to hyperandrogenic women increases the 
circulating levels of both insulin and androgens.  
3. Weight loss decreases the levels of both insulin and androgens, and increases 
the levels of IGFBP-1.  
4. The experimental reduction of insulin levels in women reduces androgen 
levels in women with polycystic ovaries, but not in normal women.  
5.   In vitro, insulin stimulates thecal cell androgen production.  
          6.  After normalization of androgens with GnRH agonist treatment, the 
hyperinsulin response to glucose tolerance testing remains abnormal in obese women 
with polycystic ovaries. 
Nevertheless, antiandrogen treatment and prolonged androgen suppression 
can ameliorate the degree of insulin resistance. However, the effect is not great, and 
may be limited to lean patients with mild hyperinsulinemia. 
 
At higher concentrations, insulin binds to the type I IGF receptors (which are 
similar in structure to insulin receptors; both IGF and insulin transmit their signals by 
initiating tyrosine autophosphorylation of their receptors). Thus, when insulin 
receptors are blocked or deficient in number, insulin would bind to the type I IGF 
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receptors. Activation of IGF-I receptors by insulin would lead to increased 
androgen production in thecal cells(9). 
 
 The endogenous insulin-like growth factor in the human ovarian follicle is IGF-
II in both the granulosa and the thecal cells. Activity of IGF-I with human ovarian 
tissue can be explained by the fact that both IGF-I and IGF-II activities can be 
mediated by the type I IGF receptor, which is structurally similar to the insulin 
receptor. 
There are two other important actions of insulin which contribute to 
hyperandrogenism in the presence of hyperinsulinemia: inhibition of hepatic 
synthesis of sex hormone-binding globulin and inhibition of hepatic production of 
insulin-like growth factor binding protein-1(9).  
 
Independent of any effect on sex steroids, increased insulin will inhibit the 
hepatic synthesis of sex hormone-binding globulin. Both insulin and IGF-I directly 
inhibit SHBG secretion by human hepatoma cells. This is now known to be the 
mechanism for the inverse relationship between body weight and the circulating levels 
of SHBG. Because SHBG is regulated by insulin, decreased SHBG levels in women 
represent an independent risk factor for noninsulin-dependent diabetes mellitus, 
regardless of body weight and fat distribution. Of course, a decrease in SHBG allows 
more androgen and estrogen to be bioavailable(10). 
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Nutritional intake decreases the circulating levels of insulin-like growth factor 
binding protein-1 (IGFBP-1) because of the increase in insulin, which then directly 
inhibits IGFBP-1 production in the liver. Obese individuals with increased insulin 
levels and women with polycystic ovaries and hyperinsulinimia  have lower 
circulating levels of IGFBP-1. This lower level of IGFBP-1 allows an increase in 
circulating levels of IGF-I and greater local activity of IGF-I and/or IGF-II in the ovary. 
 
Also, greater IGF-I activity in the endometrium due to reduced levels of 
IGFBP-1 and direct insulin activation of IGF receptors or its own receptor are possible 
mechanisms for endometrial growth and the increased risk for endometrial cancer 
in these patients. On the other hand, a greater IGF binding protein capacity in the 
follicular fluid from polycystic ovaries would yield a reduced bioavailability of IGFs 
within the follicle. Although these findings (increased circulating IGF availability and 
decreased follicular IGF availability) at first seem paradoxical, they are compatible 
with increased thecal androgen production by the IGF pathway and disrupted 
follicular maturation by the FSH system.   
 
These characteristics of polycystic ovaries are secondary to increased 
anovulation, hyperinsulinemia, and increased androgens, rather than indicating 
a primary, etiologic role (10). 
 
 Finally, there is evidence that insulin can increase LH secretion in some 
anovulatory, overweight women. Not  all patients with hyperinsulinemia also 
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hyperandrogenic; a logical speculation is that an ovarian genetic susceptibility is 
required, although it may be that the existence of long-term anovulation must be 
present and even precede hyperinsulinemia.” 
 
HYPERINSULINEMIA IN PCOS 
 
Both lean and obese women with polycystic ovaries can be found to have 
hyperinsulinemia, but not all hyperandrogenic women with polycystic ovaries (lean 
and obese) have hyperinsulinemia.  
 
“Furthermore, lean women with hyperinsulinemia do not appear to have the 
same risk of future diabetes mellitus, although clinical follow-up may in time document 
an onset later in life of noninsulin-dependent diabetes mellitus compared to an earlier 
onset in obese women  
Because of the probable inherited susceptibility for anovulation and insulin 
resistance, consideration should be given to a glucose tolerance and insulin 
evaluation for family members of already diagnosed patients. Both brothers and 
sisters of anovulatory, hyperandrogenic women can be insulin resistant(8).  
Teenagers who present with persistent anovulation would also be good 
candidates for hyperinsulinemia testing. During puberty, insulin resistance develops, 
probably because of the increase in sex steroids and growth hormone, resulting in a 
secondary increase in insulin and IGF-I. 
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All anovulatory women who are hyperandrogenic should be assessed for 
insulin resistance and glucose tolerance with measurements of: 
1. The fasting glucose:insulin ratio, followed by 
2. The 2-hour glucose level after a 75 g glucose load: 
normal less than 140 mg/dL 
impaired 140–199 mg/dL 
noninsulin-dependent diabetes mellitus 200 mg/dL and higher” 
 
  
PUBERTY AND PCOS 
 
Polycystic ovarian syndrome originates in puberty. Clinical observation teaches 
that PCOS often develops during adolescence. Excessive hair growth usually originates 
from before the onset of menstrual cycles(1). Menarche tends to be delayed. Irregular 
cycles, although considered a normal phenomenon during the first gynaecological 
years, frequentlycontinues into adulthood. 
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Mechanism of Onset of PCOS During Puberty 
Taking into account the above remarks, the following hypothesis is postulated 
 
Mechanism of onset of PCOS during puberty 
 
The onset of pulsatile growth hormone (GH) secretion during early puberty 
induces the release of IGF-1 (Insulin like growth factor-1) by the liver and most other 
tissues. GH also provokes insulin resistance, which selectively affects peripheral 
glucose. The resulting hyperinsulinaemia acting on IGF-1 causes ovarian 
hyperstimulation inducing thecal cell hyperplasia and excessive androgen 
production(2). The increased androgens cause follicular atresia and increased 
circulating oestrone levels because of peripheral conversion in adipose tissues. The 
altered endocrine milieu provokes increased pituitary LH secretion, which aggravates 
the thecal cell stimulation. 
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After puberty the insulin and IGF-1 levels progressively decline in most 
patients, resulting in normalisation of clinical and morphological picture. Only in a few 
cases PCOS persists”(2).  
 
“THE CLINICAL CONSEQUENCES OF PERSISTENT ANOVULATION 
Anovulation is the key feature of this condition and presents as amenorrhea in 
approximately 50% of cases and with irregular, heavy bleeding (dysfunctional uterine 
bleeding) in 30%(2). True virilization is rare, but 70% of anovulatory patients complain 
of cosmetically disturbing hirsutism. The development of hirsutism depends not only 
on the concentration of androgens in the blood but on the genetic sensitivity of hair 
follicles to androgens. Thus, anovulatory, hyperandrogenic women can be free of the 
clinical signs of hirsutism. Alopecia and acne can also be consequences of 
hyperandrogenism.  
Obesity has been classically regarded as an important feature, but in view of the 
concept of persistent anovulation arising from many causes, its presence is extremely 
variable (about 35–60% of anovulatory women with polycystic ovaries) and has no 
diagnostic value. However, the greater the body mass index, the higher the testosterone 
levels, and, therefore, hirsutism is more common in overweight anovulatory 
women. 
It is impossible to provide an accurate estimate of how many anovulatory 
women with polycystic ovaries have hyperinsulinemia(1). It does appear that the more 
aggressive clinicians pursue hyperinsulinemia in these patients the more often it is 
being demonstrated. Certainly not every anovulatory patient has hyperinsulinemia, not 
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even every overweight, anovulatory patient. However, subtle abnormalities in insulin 
dynamics may be present early in the course of this condition, and appear more 
prominently with time. Thus, when anovulation and hyperandrogenism are present, 
hyperinsulinemia may be an underlying disorder in most, if not all.  
 
As an anovulatory woman gains weight, the insulin resistance and 
hyperinsulinemia associated with obesity are now added to the underlying 
problem, and the abnormality is now more easily detected. Although an elevated LH 
value in the presence of a low or low-normal FSH may be diagnostic, the diagnosis is 
easily made by the clinical presentation alone. About 20–40% of patients with this 
condition do not have elevated LH levels with reversal of the LH:FSH ratio. Hence 
FSH and LH levels are not routinely measured in anovulatory patients. The 
selection of a specific criterion to make this diagnosis will inevitably fail to include 
many patients with this clinical problem that covers a broad spectrum of 
manifestations. This failing also applies to the diagnostic use of ultrasonographic 
criteria.  
 
The Clinical Consequences of Persistent Anovulation 
1. Infertility. 
2. Menstrual bleeding problems, ranging from amenorrhea to abnormal uterine 
bleeding. 
3. Hirsutism, alopecia, and acne. 
4. An increased risk of endometrial cancer and, perhaps, breast cancer. 
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5. An increased risk of cardiovascular disease. 
6. An increased risk of diabetes mellitus in patients with insulin resistance. 
 
There are potentially severe clinical consequences of the steady state of 
hormone secretion. Besides the problems of bleeding, amenorrhea, hirsutism, and 
infertility, the effect of the unopposed and uninterrupted estrogen is to place the patient 
at considerable risk for cancer of the endometrium and, perhaps, cancer of the breast. 
The risk of endometrial cancer is increased 3-fold, while chronic anovulation during 
the reproductive years has been reported to be associated with a 3–4 times increased 
risk of breast cancer appearing in the postmenopausal years. If left unattended, 
patients with persistent anovulation develop clinical problems, and, therefore, 
appropriate therapeutic management is essential for all anovulatory patients. In a long-
term follow-up of women with polycystic ovaries, the problems of android obesity 
and hyperinsulinemia were observed to persist into the postmenopausal years(8).  
 
 Postmenopausal women who have previously been anovulatory, 
hyperandrogenic, and hyperinsulinemic  experience a reduction in life expectancy 
because of cardiovascular disease and diabetes mellitus. These women will derive 
important benefits from an aggressive preventive health care attitude on the part of the 
clinician that results in amelioration of adverse metabolic risk factors. 
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The lipid profile in androgenized women with polycystic ovaries (who are also 
exposed to relatively lower estrogen levels over time) is similar to the male pattern with 
higher levels of cholesterol, triglycerides, and LDL-cholesterol, and lower levels 
of HDL-cholesterol, and this abnormal pattern is independent of body weight(10). 
Although the elevated androgens associated with polycystic ovaries and anovulation  
offer some protection against osteoporosis, the adverse impact on the risk for 
cardiovascular disease is a more important consideration. An adverse lipid profile is a 
distinguishing feature of these patients even when body mass index, insulin, and age 
are controlled in case-control studies.  
 
Hyperandrogenic and hyperinsulinemic, anovulatory women must be cautioned 
regarding their increased risk of future diabetes mellitus. Not only are anovulatory, 
hyperinsulinemic women at greater risk for noninsulin-dependent diabetes, but the age 
of onset is about 30 years earlier than the general population. Not surprising, these 
patients are more likely to develop glucose tolerance problems in pregnancy. And 
patients who have experienced gestational diabetes are more likely to demonstrate the 
entire metabolic syndrome (hyperandrogenism and hyperinsulinemia) later in life.  
 
In a long-term follow-up study, anovulatory women with polycystic ovaries had 
a 5-fold increased risk of diabetes mellitus compared with age-matched controls. It is 
appropriate, and indeed essential, to monitor glucose tolerance with periodic glucose 
tolerance testing(8). 
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Hyperinsulinemia also contributes to the increased risk of cardiovascular 
disease both by means of a direct atherogenic action and indirectly by adversely 
affecting the lipoprotein profile. Insulin resistance may be a more significant factor 
than androgens in determining the abnormal lipoprotein profile in overweight, 
anovulatory women. 
 
 It has also been suggested that the increased insulin stimulation of IGF-I could produce 
bone changes similar to that seen in acromegaly(10). Hyperinsulinemia may be a factor 
contributing to the higher risk of endometrial cancer in these patients by increasing 
IGF-I activity in the endometrium.” 
 
MANAGEMENT OF VARYING MANIFESTATIONS OF PCOS 
 
A patient with PCOS may present to a clinician at different stages of her life. 
During adolescence, she may present with menstrual irregularities, skin problems such 
as hirsutism, acne or alopecia. She may present with obesity or acanthosis nigricans. 
During the reproductive years she may present with infertility. She may present in the 
later part of her life with problems related to long-term sequelae of PCOS namely 
gynaecological cancer, diabetes or cardiovascular risk. The management of a patient 
with PCOS will depend on her presenting problems.  
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Menstrual irregularities 
Many women with PCOS will give a history of infrequent cycles and may be 
about three to six menstrual periods per year. As long as these are not unduly heavy 
or painful no particular medical therapy may be needed. In obese women, weight loss 
should be the first line of treatment. In patients who succeed to lose more than 5% of 
their body weight, this alone may restore normal menstrual regularity. “A reduction 
in body weight of 5–10% will cause a 30% reduction in visceral fat, which is often 
sufficient to restore ovulation and reduce markers of metabolic disease. Weight loss is 
associated with a reduction of circulating insulin and androgen levels, which can 
also be achieved by using insulin-sensitising drugs(10). Increased PAI-1 levels 
associated with hyperinsulinemia also improve with weight loss. These metabolic 
improvements are associated with an impressive rate of resumption of ovulation and 
pregnancy. 
 
Often an oral contraceptive can be a useful treatment for women with PCOS. 
Oral contraceptives can have the benefit of contraception, protection against 
endometrial cancer and improve skin manifestations of PCO such as hirsuitism and 
acne. Oral pills which contains 35 microgram of ethinyl oestradiol and 2 mg of 
cyproterone acetate may be a good option in patients who also have 
hyperandrogenism (hirsuitism and acne) associated with menstrual irregularity(10).  
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Skin Manifestations 
Skin manifestations of polycystic ovarian syndrome include acne, hirsutism, alopecia 
and acanthosis nigricans. 
 
 Acne is seen in approximately one-third of PCOS patients. Mild acne can be 
treated topically with keratolytics such as azelaic acid, retinoids, or with 
antibacterials such as benzoyl peroxide, clindamycin 1% lotion and erythromycin 
2% gel(4). More severe forms generally require oral antibiotics such as the 
tetracyclines, erythromycin and trimethoprim. For severe case, isotretinoin is 
prescribed and produces long-term remission in more than 70% of patients”. 
 
In PCOS, antiandrogens are most effective because acne occurs as a result of 
overstimulation of the pilosebaceous unit 3by androgens. Antiandrogens that can be 
used are cyproterone acetate, spironolactone, flutamide and finasteride. 
Cyproterone acetate can be given as a combined oral contraceptive pill This minimal 
dose has proven effective in almost 100% of cases. In more severe cases, cyproterone 
acetate in a dose of 10–100 mg/day can be given on the first 10 days of the combined 
oral contraceptive pill. It will take 3–5 months before any improvement can be seen. 
Acne will be cleared in 60% of patients in 6 months and after 12 months, 95% should 
be free of acne. 
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Spironolactone, an aldosterone antagonist has antiandrogen action. Flutamide, 
a nonsteroidal antiandrogen can be used for the treatment of hirsutism and acne. 
However because of rare reports of hepatotoxicity it is not commonly used. Finasteride 
acts by inhibiting 5 α reductase can be taken orally in dose of 1–5 mg/day. It does not 
have much side effects. When spironolactone, finasteride and flutamide is taken, 
contraception is advised to avoid the potential risk of feminisation of a male 
foetus(4). It is important to inform patients that clinical response takes time and patients 
have to be on long-term maintenance treatment to avoid relapse. The longer the 
duration of treatment (at least in the ethinyl oestradiol/cyproternone acetate oral 
contraceptive pills), the less the chance of relapse within a given period of time. 
 
Hirsutism 
Patient may present with excess hair as their main problem.  Hirsuitism can be 
treated with physical therapy such as bleaching, shaving, plucking, depilatory 
creams, electrolysis and laser. Bleaching of the hair with hydrogen peroxide is used 
to disguise pigmented facial hairs. Repeated plucking of hair is another method but 
may lead to permanent hair follicle matrix damage, resulting in finer, thinner hair. Side 
effects include postinflammatory hyperpigmentation, folliculitis, pseudofolliculitis 
and, rarely scarring. 
 
 Chemical depilators are usually thioglycates that disrupt the disulphide bonds 
of hair shaft. Electrolysis is a proven method of hair removal. Three forms exist, 
galvanic (direct current electrolysis), thermolysis (alternate current electrolysis) 
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and the blend (galvanic electrolysis and thermolysis)(3). Side effects include 
erythema, hyperpigmentation and hypopigmentation, blistering and pain. Usually 
several treatments are required to improve efficacy. 
 
A combined oral contraceptive pill will usually prevent new areas of excess hair 
from occurring but rarely are sufficient alone to cause regression of excess hair. This 
usually necessitates the addition of an antiandrogen therapy such as cyproterone acetate 
(CPA). Most women notice a regression of excess hair within 4–6 months but typically 
treatment needs to be continued for at least 1–2 years to substantially reduce hair 
growth and then maintenance therapy is required to keep the problem under control. 
Typically this is a low dose combined oral contraceptive pill. Another useful 
antiandrogenic treatment is spironolactone. This may be used alone or in combination 
with a contraceptive pill. Flutamide and Finasteride are also drugs that help reduce 
hirsuitism. 
 
Alopecia 
Some patients may present with alopecia. Treatment includes psychological 
support and hairstyling. Drugs such as minoxidil, cyproterone acetate, spironolactone 
and finasteride can be used but have limited role.(9) 
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Infertility 
Infertility is a common presenting problem in patients with polycystic ovarian 
syndrome. PCOS is associated with approximately 80–90% of women who suffer from 
infertility due to anovulation. Therapy of most anovulatory patients can be planned at 
the first visit. If the patient desires pregnancy, she is a candidate for the medical 
induction of ovulation. When pregnancy is achieved, patients with polycystic ovaries 
appear to have an increased risk of spontaneous miscarriage(9). This increased risk has 
been attributed to elevated levels of LH that may produce an adverse environment for 
the oocyte, perhaps even inducing premature maturation and completion of the first 
meiotic division. For this reason, consideration should be given to pretreatment 
suppression prior to the induction of ovulation.  
 
 There are several methods in inducing ovulation and basically they are 
reduction of insulin concentrations, FSH stimulation or a reduction of LH 
concentration—or a combination of these. 
 
Role Weight Loss 
The first step in ovulation induction is weight loss. Obese women (BMI >30 
kg/m2) should be encouraged to lose weight. Even patients who are overweight (BMI 
> 27 kg/m2) are associated with a reduced chance of ovulation. Weight loss improves 
the endocrine profile, and the likelihood of ovulation and a healthy pregnancy(10). 
Achieving weight reduction is, however, extremely difficult, particularly as the 
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metabolic status of the patient with PCOS conspires against weight loss. Different 
strategies can be used to effect weight loss. Dieting and exercise should be encouraged. 
 
Ovulation induction 
The simplest mode of ovulation induction is the use of clomiphene citrate. 
Patients can be started with 50 mg a day orally, for 5 days starting from day 2 to day 6 
of a spontaneous or progesterone-induced bleed. Serial transvaginal ultrasound is a 
good method of looking at the follicles. This can be done on  day 10 or 11 of her cycle 
and depending on the presence and size of follicle, serial scans can be done to assist 
patients to determine her fertile period. Another method is the use of urinary LH test(8).  
Addition of dexamethasone at the follicular phase of the cycle has given better results. 
Besides clomiphene citrate, the other antioestrogen that can be used is tamoxifen. 
Letrozole an oral aromatase inhibitor is another drug that may have potential in 
ovulation induction. 
 
Amenorrhea 
“If the patient presents with amenorrhea, investigations must be pursued.  For 
the patient who does not wish to become pregnant and does not complain of hirsutism, 
but is anovulatory and has irregular bleeding(8),  therapy is directed toward interruption 
of the steady state effect on the endometrium and breast. The use of 
medroxyprogesterone acetate (5–10 mg daily for the first 10 days of every month) 
is favored to ensure complete withdrawal bleeding and to prevent endometrial 
hyperplasia and atypia.  
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The monthly 10-day duration has been demonstrated to be essential to protect 
the endometrium from cancer in women on postmenopausal estrogen therapy. Young, 
anovulatory women also require at least 10 days of progestational exposure every 
month. The patient will be aware of the onset of ovulatory cycles because bleeding will 
occur at a time other than the expected withdrawal bleed. 
 
  When reliable contraception is essential, the use of low-dose combination oral 
contraception in the usual cyclic fashion is appropriate. Besides contraception, 
there is another argument in favor of continuous suppression with low-dose oral 
contraceptives rather than periodic progestational interruption. 
 
Role of Oral contraceptives 
Monthly periodic treatment with a progestational agent has no significant effect 
on the androgen production by polycystic ovaries. Thus, if contraception is not 
required and hirsutism is not a complaint, assessment of the lipoprotein profile is 
a reasonable clinical response, and in the presence of a male pattern, serious 
consideration should be given to suppression with oral contraceptives(9). Short-term 
studies with low-dose oral contraceptives have not revealed an adverse effect on the 
already abnormal lipid profile. Indeed, one would expect an improvement in the lipid 
profile to accompany suppression of androgen production.  
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Similarly, interference with androgen actions with an agent like flutamide 
improves the lipid profile. Long-term suppression of hyperandrogenism should be 
beneficial. Because older, high-dose oral contraceptives increased insulin resistance, it 
has been suggested that this treatment should be avoided in anovulatory, overweight 
women. However, low-dose oral contraceptives have minimal effects on 
carbohydrate metabolism, and the majority of hyperinsulinemic, hyperandrogenic 
women can be expected to respond favorably to treatment with oral contraceptives. 
Insulin and glucose changes with low-dose (less than 50 μg ethinyl estradiol) oral 
contraceptives are so minimal, that it is now believed that they are of no clinical 
significance.  
 
 Finally, the administration of a low-dose oral contraceptive to women with 
extreme obesity and insulin resistance resulted in only a mild deterioration of glucose 
tolerance. This experience supports the safety of oral contraceptive treatment for 
anovulatory, hyperandrogenic, hyperinsulinemic women. Patients resistant to oral 
contraceptive treatment may require suppression with a GnRH agonist. Because 
glucocorticoids increase insulin resistance, they should be used with caution in patients 
with hyperinsulinemia. Spironolactone and flutamide do not affect insulin sensitivity 
in anovulatory women.  
 
A contributing factor to the abnormal lipid pattern in many of these patients is 
hyperinsulinemia, and therefore, a major effort must be directed to control of body 
weight in those patients who are overweight(8).  
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Role of drugs 
The best application of drugs, such as metformin and troglitazone, remains to 
be determined by data from appropriate clinical trials; however, the mechanism of 
action and the logic behind this treatment offer impressive potential for preventive 
health benefits for these women. Clinical (ovulatory) and laboratory responses can be 
expected within 3 months. These drugs will prove to be an important component of 
the health care of anovulatory women with polycystic ovaries(9). 
 
Although changes are uncommon, liver function must be monitored during 
troglitazone treatment. Troglitazone was found to be associated with a 30% decrease 
in the circulating estrogen and progestin levels in oral contraceptive users in a small 
number of women who have been studied in clinical trials, an effect probably 
secondary to troglitazone's stimulation of hepatic enzyme activity; however, it is by no 
means certain that this will result in a loss of contraceptive efficacy.  
 
Lactic acidosis is a rare complication in patients treated with metformin; 
however, virtually all cases have occurred in patients with complicated medical 
problems, such as sepsis, renal insufficiency, and congestive heart failure. Patients who 
become ill should discontinue metformin treatment, and metformin should not be 
administered to women who have abnormal renal chemistries. 
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Treatment with low doses of dehydroepiandrosterone to increase insulin 
sensitivity is effective in the short-term, but well-designed studies are necessary to 
demonstrate long-term efficacy and safety.” 
 
METFORMIN 
Metformin improves insulin sensitivity. Metformin treatment (500 mg 8-hourly) 
reduces hyperinsulinaemia, basal and stimulated LH levels and free testosterone 
concentrations in overweight women with polycystic ovaries. 
 
Mechanism of Action of Metformin 
“Metformin therapy improves insulin sensitivity shown by a reduction in fasting 
plasma glucose and insulin concentrations. It is not effective in the absence of insulin. 
a. Metformin decreases basal hepatic glucose output in patients, producing 
an important mechanism through which the drug lowers fasting plasma 
glucose concentration. 
b. Metformin has increased glucose disposal in most studies using 
hyperinsulinaemic—euglycaemic and hyperglycaemic—clamp procedures, 
with muscle implicated as its main site of action. 
c. Metformin also increases the uptake and oxidation of glucose by adipose 
tissue as well as lipogenesis. However, the actions of metformin on peripheral 
tissues in vitro require high concentrations and are slow in onset. 
d. Metformin increases the binding of insulin to its receptors, 
phosphorylation and tyrosine kinase activity of insulin receptors in vivo, 
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but these action may be due to reduced plasma glucose concentrations, since 
they cannot be reproduced in vitro. 
e. Metformin also increases translocation of the GLUT-1 and GLUT-4 
isoforms of glucose transporters in different types of cells, and it prevents 
the development of insulin resistance in cultured hepatocytes and adipocytes 
for long periods to high insulin concentrations. 
 
Firstly there should not be any contraindications ofmetformin use. The 
contraindications include diminished renal function, cardiac diseases, severe 
pulmonary diseases, liver dysfunction, pancreatitis, concomitant use of diuretics 
and hypersensitivity to metformin. Patients must be informed about the adverse 
effects, which include gastrointestinal (GI) symptoms such as diarrhoea, nausea, 
vomiting especially during the initial treatment periods. These symptoms are usually 
transient and resolve spontaneously.  
 
Gastrointestinal symptoms can be avoided if metformin is taken with meals 
and if the dose is increased slowly like one per day for the first week and two per day 
the next week and making into three per week throughout the treatment period will 
reduce the GI problems. Probably because of the GI side effects, some patient may 
have weight loss. Patients may return to ovulatory cycles. Insulin sensitising agent 
troglitazone appears to be of benefit to PCOS patient but it has been withdrawn from 
the market because of reports of death from hepatotoxicity. The other thiazolidinedione 
that is being investigated is rosiglitazone. In addition to difficulty conceiving, women 
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with PCOS are at increased risk of miscarriage following either spontaneous or assisted 
conception.  
. 
Laparoscopic ovarian drilling is a simple procedure whereby several punctures 
are made in one or both the polycystic ovaries. This technique has superseded 
ovarian wedge resection. The controversy is how many diathermy points and at what 
wattage is to be used during ovarian cautery. It is now recommended that each ovary 
only about five to eight points are done with 300–400. The risk of ovarian diathermy 
is periovarian adhesions and the possibility of ovarian failure. Abdominal lavage has 
helped reduce these periovarian adhesions. Besides diathermy, laser can be used to 
perform ovarian drilling 
. 
Gonadotrophin therapy is indicated for women with anovulatory PCOS who 
have been treated with antioestrogens, either if they have failed to ovulate or if they 
have a response to clomiphene that is likely to reduce their chance of conception (e.g. 
persistent hypersecretion of LH, or negative post coital tests due to the antioestrogenic 
effect on cervical mucus). The aim is for unifollicular development and this can be 
challenging. There are many protocols available but the more recent and probably the 
best protocol is the sequential step up, step down protocol. Patients are started with 
very low dose gonadotrophin (FSH) and the dose is gradually increased. 
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  When the leading follicle reaches 14 mm, the FSH threshold dose is reduced 
by half. This protocol appears to reduce the number of lead follicles when compared 
with a classic step up protocol. The aim of this low-dose step up protocol is to reduce 
the risk of both multiple pregnancies and ovarian hyperstimulation syndrome, both of 
which are increased in women with PCO compared with normal ovaries(9). 
  
 Treatment cycles can be very long, up to 28–35 days. When the leading follicle 
reaches 17 mm in its largest diameter, human chorionic gonadotrophin (hCG) 10,000 
units is given to trigger ovulation. Some believe that there may be benefit in waiting 
until the follicle reaches 20 mm. Sometimes there may be sudden increase in the 
number of follicles. When this happen the cycle can be cancelled or converted to in 
vitro fertilisation. 
 
In some patients, in vitro fertilisation (IVF) or even intracytoplasmic sperm 
injection (ICSI) may be the only option for pregnancy. Patient with PCOS with tubal 
blockage or with husband/male partners with low sperm counts may have to undergo 
IVF or IVF-ICSI. Many protocols are available when performing IVF. The most 
commonly performed protocol for IVF is the long protocol using gonadotrophin 
agonist to down regulate and followed by gonadotrophin stimulation of the ovary. This 
protocol is ideal for patients with PCO. The reason is that PCO patients have high LH 
levels. This is detrimental to pregnancy rates and also causes high miscarriage rate. As 
such, by pituitary downregulation, serum LH is reduced(9). It is also important to start 
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these patients with low dose FSH. These patients must also be monitored closely with 
daily ultrasound from day eight of stimulation. 
 
Collection of immature oocytes from PCOS patient is being researched. The 
immature oocytes can be matured in vitro and inseminated or intracytoplasmic sperm 
injection (ICSI) could be performed. 
 
Carotid ultrasonography 
“Subclinical atherosclerosis can be demonstrated by carotid 
ultrasonography to be prevalent in premenopausal women with a history of 
anovulation and polycystic ovaries(9). In women undergoing coronary angiography, 
the prevalence of polycystic ovaries is increased, and women with polycystic ovaries 
have more extensive coronary atherosclerosis. Thus anovulatory women with 
polycystic ovaries develop risk factors for atherosclerosis and ultimately clinical 
disease, comparable with that found in older, very overweight, postmenopausal 
women. 
Family counseling 
Growing support for an inherited basis for this disorder (autosomal dominant) 
makes it important to consider appropriate family counseling. Sisters and daughters 
may have a 50% chance of having the same problems as the patient. The typical patient 
presents with anovulation and irregular menses or amenorrhea with withdrawal 
bleeding after a progestational challenge.  
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Documentation of anovulation is usually unnecessary, especially in the presence 
of menstrual irregularity with periods of amenorrhea. In the patient who has long-
standing anovulation, an endometrial biopsy (with extensive sampling) is a wise 
precaution. The well-known association between this condition and abnormal 
endometrial changes must be kept in mind. Endometrial cancer can be encountered in 
young, anovulatory women. The decision to perform an endometrial biopsy should 
not be influenced by the patient's age. It is the duration of exposure to unopposed 
estrogen that is critical(9).”  
 
“METABOLIC SYNDROME 
The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a 
collection of metabolic abnormalities that confer increased risk of cardiovascular 
disease (CVD) and diabetes mellitus. The major features of the metabolic syndrome 
include central obesity, hypertriglyceridemia, low levels of high-density 
lipoprotein (HDL) cholesterol, hyperglycemia, and hypertension (2). 
 
EPIDEMIOLOGY 
The most challenging feature of the metabolic syndrome to define is waist 
circumference. Intraabdominal circumference (visceral adipose tissue) is 
considered most strongly related to insulin resistance and risk of diabetes and CVD, 
and for any given waist circumference the distribution of adipose tissue between SC 
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and visceral depots varies substantially. Thus, within and between populations, there is 
a lesser vs. greater risk at the same waist circumference. These differences in 
populations are reflected in the range of waist circumferences considered to confer risk 
in different geographic locations. 
 
          The prevalence of the metabolic syndrome varies around the world, in part 
reflecting the age and ethnicity of the populations studied and the diagnostic criteria 
applied. In general, the prevalence of the metabolic syndrome increases with age. 
Moreover, the rising prevalence and severity of obesity among children is reflected in 
features of the metabolic syndrome in a younger population(1). 
 
DEFINITION OF METABOLIC SYNDROME 
 There are various emerging definitions for metabolic syndrome. It is defined 
according to the modified American Heart Association/National Heart Lung Blood 
Institute AHA/NHLBI (ATP III 2005) definition. The main changes in this definition 
include (i) defining the ethnic-specific difference in central obesity by using the 
World Health Organization recommendation for waist circumference ≥80 cm in 
Asian women, and (ii) and reducing the threshold for impaired fasting glucose to 100 
mg% in accordance with the American Diabetes Association revised definition”. 
The International Diabetes Federation (IDF) has introduced a new definition, 
combining both clinical and research needs with a slight modification in the ATP-III 
definition in 2005 where presence of abdominal obesity was considered mandatory for 
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MS diagnosis(12). 
“IDF experts recognized that there was a stark need for a single, universally 
accepted diagnostic tool which is easy to use in clinical practice and that does not rely 
upon measurements only available in research settings. The new IDF definition 
addresses both clinical and research needs,providing an accessible, diagnostic tool 
suitable for worldwide use and establishing a comprehensive ‘platinum standard’ list 
of additional criteria that should be included in epidemiological studies and other 
research into the metabolic syndrome(12).” 
 
“WORLDWIDE DEFINITION OF METABOLIC SYNDROME 
The New International Diabetes Federation (IDF) definition 
According to the new IDF definition, for a person to be defined  as having the 
metabolic syndrome they must have:” 
Central obesity (defined as waist circumference * with ethnicity specific 
values,≥80 cm for south asian women) 
“Plus any two of the following four factors: 
Raised 
 Triglycerides 
≥150 mg/dL (1.7mmol/L) 
Or specific treatment for this lipid abnormality 
Reduced HDL  
Cholesterol 
< 40 mg/dL (1.03 mmol/L) in males 
< 50 mg/dL 91.29 mmol/L) in females 
Or specific treatment for this lipid abnormality 
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Raised blood  
Pressure 
Systolic BP  ≥130 mg/dL or diastolic BP ≥85 mm 
Hg or treatment of previously diagnosed 
hypertension 
Raised fasting 
Plasma glucose 
(FPG) ≥100 mg/dL (5.6 mmol/L) 
Or previously diagnosed typed 2 diabetes 
If above 5.6 mmol/L or 100 mg/dL, OGTT is 
strongly recommended but is not necessary to 
define presence of the syndrome, 
. * If BMI is > 30 kg/m2, Central obesity can be assumed and waist 
circumference does not need to be measured.” 
 
RISK FACTORS 
 
Overweight/Obesity 
 Central adiposity is a key feature of the syndrome, and the syndrome’s 
prevalence reflects the strong relationship between waist circumference and increasing 
adiposity. However, despite the importance of obesity, patients who are of normal 
weight may also be insulin resistant and may have the metabolic syndrome(10). 
 
Sedentary Lifestyle  
Physical inactivity is a predictor of CVD events and the related risk of death. 
Many components of the metabolic syndrome are associated with a sedentary lifestyle, 
including increased adipose tissue (predominantly central), reduced HDL cholesterol, 
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and increased triglycerides, blood pressure, and glucose in genetically susceptible 
persons. Compared with individuals who watch television or videos or use the 
computer <1 h daily, those who do so for >4 h daily have a twofold increased risk of 
the metabolic syndrome(12). 
 
Aging  
The age dependency of the syndrome’s prevalence is seen in most populations around 
the world. 
 
Diabetes Mellitus  
Diabetes mellitus is included in both the NCEP and the harmonizing definitions 
of the metabolic syndrome. Great majority (~75%) of patients with type 2 diabetes or 
impaired glucose tolerance have the metabolic syndrome. The presence of the 
metabolic syndrome in these populations relates to a higher prevalence of CVD than 
in patients who have type 2 diabetes or impaired glucose tolerance but do not have this 
syndrome”. 
 
Cardiovascular Disease  
“Individuals with the metabolic syndrome are twice as likely to die of 
cardiovascular disease as those who do not, and their risk of an acute myocardial 
infarction or stroke is threefold higher(8). The approximate prevalence of the 
metabolic syndrome among patients with coronary heart disease (CHD) is 50%, with a 
prevalence of ~35% among patients with premature coronary artery disease (before or 
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at age 45) and a particularly high prevalence among women. With appropriate cardiac 
rehabilitation and changes in lifestyle (e.g., nutrition, physical activity, weight 
reduction, and—in some cases—pharmacologic therapy), the prevalence of the 
syndrome can be reduced. 
 
Lipodystrophy  
Lipodystrophic disorders in general are associated with the metabolic 
syndrome. Both genetic lipodystrophy  and acquired lipodystrophy (e.g., HIV-related 
lipodystrophy in patients receiving antiretroviral therapy) may give rise to severe 
insulin resistance and many of the components of the metabolic syndrome. 
ETIOPATHOGENESIS OF METABOLIC SYNDROME 
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Insulin Resistance  
The most accepted hypothesis to describe the pathophysiology of the metabolic 
syndrome is insulin resistance as in PCOS.The onset of insulin resistance is heralded 
by postprandial hyperinsulinemia, which is followed by fasting hyperinsulinemia and 
ultimately by hyperglycemia. An early major contributor to the development of insulin 
resistance is an overabundance of circulating fatty acids(10). 
 
The inhibition of lipolysis in adipose tissue is the most sensitive pathway of 
insulin action. Thus, when insulin resistance develops, increased lipolysis produces 
more fatty acids, which further decrease the antilipolytic effect of insulin. Excessive 
fatty acids enhance substrate availability and create insulin resistance by 
modifying downstream signaling. Fatty acids impair insulin-mediated glucose uptake 
and accumulate as triglycerides in both skeletal and cardiac muscle, whereas increased 
glucose production and triglyceride accumulation take place in the liver. Leptin 
resistance has also been raised as a possible pathophysiologic mechanism to explain 
the metabolic syndrome(12).  
 
Not only is hypertriglyceridemia a feature of the metabolic syndrome, but 
patients with the metabolic syndrome have elevated levels of ApoCIII carried on 
VLDLs and other lipoproteins. This increase in ApoCIII is inhibitory to lipoprotein 
lipase, further contributing to hypertriglyceridemia and also associated with more 
atherosclerotic cardiovascular disease. 
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The other major lipoprotein disturbance in the metabolic syndrome is a 
reduction in HDL cholesterol. This reduction is a consequence of changes in HDL 
composition and metabolism. In the presence of hypertriglyceridemia, a decrease in the 
cholesterol content of HDL is a consequence of reduced cholesteryl ester content of the 
lipoprotein core in combination with cholesteryl ester transfer protein– mediated 
alterations in triglyceride that make the particle small and dense. This change in 
lipoprotein composition also results in increased clearance of HDL from the 
circulation.  
 
These changes in HDL have a relationship to insulin resistance that is 
probably indirect, occurring in concert with the changes in triglyceride-rich lipoprotein 
metabolism. In addition to HDLs, low-density lipoproteins (LDLs) are modified in 
composition in the metabolic syndrome. With fasting serum triglycerides at >2.0 mM 
(~180 mg/dL), there is almost always a predominance of small, dense LDLs, which are 
thought to be more atherogenic although their association with hypertriglyceridemia 
and low HDLs make their independent contribution to CVD events difficult to assess. 
Individuals with hypertriglyceridemia often have increases in cholesterol content of 
both VLDL1 and VLDL2 subfractions and in LDL particle number.Both of these 
lipoprotein changes may contributeto atherogenic risk in patients with the 
metabolicsyndrome”. 
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“Glucose Intolerance 
Defects in insulin action in the metabolic syndrome lead to impaired 
suppression of glucose production by the liver and kidney and reduced glucose 
uptake and metabolism in insulin-sensitive tissues—i.e., muscle and adipose tissue. 
To compensate for defects in insulin action, insulin secretion and/or clearance must be 
modified so that euglycemia is sustained. Ultimately, this compensatory mechanism 
fails, usually because of defects in insulin secretion, resulting in progression from 
impaired fasting glucose and/ or impaired glucose tolerance to diabetes mellitus. 
 
Hypertension 
 The relationship between insulin resistance and hypertension is well 
established. Paradoxically, under normal physiologic conditions, insulin is a 
vasodilator with secondary effects on sodium reabsorption in the kidney. However, in 
the setting of insulin resistance, the vasodilatory effect of insulin is lost but the renal 
effect on sodium reabsorption is preserved. Sodium reabsorption is increased in whites 
with the metabolic syndrome but not in 
Africans or Asians(12). 
 
 Insulin also increases the activity of the sympathetic nervous system, an 
effect that may be preserved in the setting of insulin resistance. Insulin resistance is 
characterized by pathway specific impairment in phosphatidylinositol-3-kinase 
signaling. In the endothelium, this impairment may cause an imbalance between the 
production of nitric oxide and the secretion of endothelin 1, with a consequent 
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decrease in blood flow. Although these mechanisms are provocative, evaluation of 
insulin action by measurement of fasting insulin levels or by homeostasis model 
assessment shows that insulin uncertain, interaction among genetic predisposition, diet, 
and the intestinal flora is important. 
 
Increased Waist Circumference 
 Waist circumference is an important component of the most recent and 
frequently applied diagnostic criteria for the metabolic syndrome. However, 
measuring waist circumference does not reliably distinguish increases in SC adipose 
tissue from those in visceral fat; this distinction requires CT or MRI. With increases in 
visceral adipose tissue, adipose tissue–derived free fatty acids are directed to the liver. 
In contrast, increases in abdominal SC fat release lipolysis products into the systemic 
circulation and avert more direct effects on hepatic metabolism. Relative increases in 
visceral versus SC adipose tissue with increasing waist circumference in Asians 
and Asian Indians may explain the greater prevalence of the syndrome in those 
populations than in African-American men, in whom SC fat predominates(12). It is also 
possible that visceral fat is a marker for but not the source of excess postprandial free 
fatty acids in obesity. 
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Dyslipidemia   
In general, free fatty acid flux to the liver is associated with increased production 
of ApoB-containing, triglyceride-rich, very low-density lipoproteins (VLDLs). The 
effect  of insulin on this process is complex, but  resistance contributes only partially 
to the increased prevalence of hypertension in the metabolic syndrome(10). 
 
Another possible mechanism underlying hypertension in the metabolic 
syndrome is the vasoactive role of perivascular adipose tissue. Reactive oxygen 
species released by NADPH oxidase impair endothelial function and result in local 
vasoconstriction. Other paracrine effects could be mediated by leptin or other 
proinflammatory cytokines released from adipose tissue, such as tumor necrosis factor 
α. Hyperuricemia is another consequence of insulin resistance and is commonly 
observed in the metabolic syndrome. There is growing evidence not only that uric acid 
is associated with hypertension but also that reduction of uric acid normalizes blood 
pressure in hyperuricemic adolescents with hypertension. The mechanism appears 
to be related to an adverse effect of uric acid on nitric acid synthase in the macula densa 
of the kidney and stimulation of the renin-angiotensin aldosterone system. 
 
Proinflammatory Cytokines  
The increases in proinflammatory cytokines— including interleukins 1, 6, and 
18; resistin; tumor necrosis factor α; and the systemic biomarker C-reactive 
protein—reflect overproductionby the expanded adipose tissue mass(12).  
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Adiponectin  
Adiponectin is an anti-inflammatory cytokine produced exclusively by 
adipocytes. Adiponectin enhances insulin sensitivity and inhibits many steps in the 
inflammatory process. In the liver adiponectin inhibits the expression of 
gluconeogenic enzymes and the rate of glucose production. In muscle, adiponectin 
increases glucose transport and enhances fatty acid oxidation, partially through the 
activation of AMP kinase. Adiponectin levels are reduced in the metabolic syndrome.  
 
CLINICAL FEATURES 
Symptoms and Signs  
The metabolic syndrome typically is not associated with symptoms. On physical 
examination, waist circumference may be expanded and blood pressure elevated. 
The presence of either or both of these signs should prompt the clinician to search for 
other biochemical abnormalities that may be associated with the metabolic syndrome. 
Less frequently, lipoatrophy or acanthosis nigricans is found on examination. 
Because these physical findings characteristically are associated with severe insulin 
resistance, other components of the metabolic syndrome should be expected(12). 
 
Associated Diseases  
Cardiovascular disease- The relative risk for new onset CVD in patients with the 
metabolic syndrome who do not have diabetes averages 1.5–3 fold. 
 Type II  Diabetes-Overall, the risk for type 2 diabetes among patients with the 
metabolic syndrome is increased three- to fivefold.  
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Other Associated Conditions 
 Those alterations include increases in ApoB and ApoCIII, uric acid, prothrombotic 
factors (fibrinogen,plasminogen activator inhibitor 1), serum viscosity, asymmetric 
dimethylarginine, homocysteine, white blood cell count, proinflammatory cytokines, 
C-reactive protein, microalbuminuria, nonalcoholic fatty liver disease and/or 
nonalcoholic steatohepatitis, polycystic ovary syndrome, and obstructive sleep apnea. 
Polycystic ovary syndrome is highly associated with insulin resistance (50–80%) and 
the metabolic syndrome, with a prevalence of the syndrome between 40% and 50%. 
Women with polycystic ovary syndrome are two to four times more likely to have the 
metabolic syndrome than are women without polycystic ovary syndrome(12). 
 
MANGEMENT OF METABOLIC SYNDROME 
LIFESTYLE 
Obesity is the driving force behind the metabolic syndrome. Thus, weight 
reduction is the primary approach to the disorder. With weight reduction, improvement 
in insulin sensitivity is often accompanied by favorable modifications in many 
components of the metabolic syndrome. In general, recommendations for weight loss  
include a combination of caloric restriction, increased physical activity, and 
behavior modification. Caloric restriction is the most important component, whereas 
increases in physical activity are important for maintenance of weight loss(12). Some 
but not all evidence suggests that the addition of exercise to caloric restriction may 
promote greater weight loss from the visceral depot. The tendency for weight regain 
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after successful weight reduction underscores the need for long-lasting behavioral 
changes. 
 
Diet 
 Before prescribing a weight-loss diet, it is important to emphasize that it has 
taken the patient a long time to develop an expanded fat mass; thus, the correction need 
not occur quickly. Given that ~3500 kcal = 1 lb of fat, ~500-kcal restriction daily 
equates to weight reduction of 1 lb per week. Diets restricted in carbohydrate typically 
provide a rapid initial weight loss. However, after 1 year, the amount of weight 
reduction is minimally reduced or no different from that with caloric restriction alone. 
Thus, adherence to the diet is more important than which diet is chosen. Moreover, 
there is concern about low-carbohydrate diets enriched in saturated fat, particularly for 
patients at risk for CVD. Therefore, a high-quality dietary pattern—i.e., a diet enriched 
in fruits, vegetables, whole grains, lean poultry, and fish—should be encouraged to 
maximize overall health benefit.(12) 
 
Physical Activity  
Before a physical activity recommendation is provided to patients with the 
metabolic syndrome, it is important to ensure that the increased activity does not incur 
risk. Some high-risk patients should undergo formal cardiovascular evaluation 
before initiating an exercise program. For an inactive participant, gradual increases in 
physical activity should be encouraged to enhance adherence and avoid injury. 
Although increases in physical activity can lead to modest weight reduction, 60–90 
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min of daily activity is required to achieve this goal. Even if an overweight or obese 
adult is unable to undertake this level of activity at least 30 min of moderate-intensity 
activity daily, a significant health benefit will follow from.(10) 
 
The caloric value of 30 min of a variety of activities can be found . Of note, a 
variety of routine activities, such as gardening, walking, and housecleaning, require 
moderate caloric expenditure. Thus, physical activity need not be defined solely in 
terms of formal exercise such as jogging, swimming, or tennis. 
 
Behavior Modification Behavioral treatment typically includes recommendations for 
dietary restriction and more physical activity, resulting in weight loss that benefits 
metabolic health. The subsequent challenge is the duration of the program because 
weight regain so often follows successful weight reduction. Long-term outcomes may 
be enhanced by a variety of methods, such as the Internet, social media, and telephone 
follow-up to maintain contact between providers and patients.(12) 
 
Obesity   
In some patients with the metabolic syndrome, treatment options need to extend 
beyond lifestyle intervention. Weight-loss drugs come in two major classes: appetite 
suppressants and absorption inhibitors. Appetite suppressants approved by the U.S. 
Food and Drug Administration include phentermine (for short-term use [3 months] 
only) as well as the more recent additions phentermine/topiramate and lorcaserin, 
which are approved without restrictions on the duration of therapy. In clinical trials, 
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the phentermine/topiramate combination has resulted in ~10% weight loss in 50% of 
patients. Side effects include palpitations, headache, paresthesias, constipation, and 
insomnia. Lorcaserin results in less weight loss—typically ~5% beyond placebo—but 
can cause headache and nasopharyngitis. Orlistat inhibits fat absorption by ~30% and 
is moderately effective compared with placebo (~5% more weight loss). Orlistat has 
been shown to reduce the incidence of type 2 diabetes, an effect that was especially 
evident among patients with impaired glucose tolerance at baseline. This drug is often 
difficult of take because of oily leakage per rectum. Metabolic or bariatric surgery is 
an option for patients with the metabolic syndrome who have a body mass index >40 
kg/m2, or >35 kg/m2 with comorbidities. An evolving application for metabolic 
surgery includes patients with a body mass index as low as 30 kg/m2 and type 2 
diabetes. Gastric bypass or vertical sleeve gastrectomy results in dramatic weight 
reduction and improvement in the features of the metabolic syndrome. A survival 
benefit with gastric bypass has also been realized.(10) 
 
LDL CHOLESTEROL  
The rationale for the NCEP:ATPIII’s development of criteria for the metabolic 
syndrome was to go beyond LDL cholesterol in identifying and reducing the risk of 
CVD. The working assumption by the panel was that LDL cholesterol goals had 
already been achieved and that increasing evidence supports a linear reduction in CVD 
events as a result of progressive lowering of LDL cholesterol with statins. For patients 
with the metabolic syndrome and diabetes, a statin should be prescribed. For those 
patients with diabetes and known CVD, the current evidence supports a maximum of 
73 
penultimate dose of a potent statin (e.g., atorvastatin or rosuvastatin). For those patients 
with the metabolic syndrome but without diabetes, a score that predicts a 10-year CVD 
risk exceeding 7.5% should also take a statin. With a 10-year risk of <7.5%, use of 
statin therapy is not  evidence based(12). 
 
 
TRIGLYCERIDES  
The NCEP:ATPIII has focused on non-HDL cholesterol rather than on 
triglycerides. However, a fasting triglyceride value of <150 mg/dL is recommended. In 
general, the response of fasting triglycerides relates to the amount of weight reduction 
achieved: a weight reduction of >10% is necessary to lower fasting triglyceride levels. 
A fibrate (gemfibrozil or fenofibrate) is the drug of choice to lower fasting triglyceride 
levels, which are typically reduced by 30–45%. 
 
HDL CHOLESTEROL  
Very few lipid-modifying compounds increase HDL cholesterol levels. Statins, 
fibrates, and bile acid sequestrants have modest effects (5–10%), whereas ezetimibe 
and omega-3 fatty acids have no effect. Nicotinic acid is the only currently available 
drug with predictable HDL cholesterol-raising properties. The response is dose related, 
and nicotinic acid can increase HDL cholesterol by ~30% above baseline(12).  
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BLOOD PRESSURE  
The direct relationship between blood pressure and all-cause mortality rate has 
been well established in studies comparing patients with hypertension (>140/90 
mmHg), patients with pre-hypertension(>120/80 mmHg but <140/90 mmHg), and 
individuals with normal blood pressure (<120/80 mmHg). In patients who have the 
metabolic syndrome without diabetes, the best choice for the initial antihypertensive 
medication is an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II 
receptor blocker, as these two classes of drugs appear to reduce the incidence of new-
onset type 2 diabetes(10). 
 
In all patients with hypertension, a sodium-restricted dietary pattern enriched in 
fruits and vegetables, whole grains, and low-fat dairy products should be advocated. 
Home monitoring of blood pressure may assist in maintaining good blood-pressure 
control. 
 
IMPAIRED FASTING GLUCOSE  
In patients with the metabolic syndrome and type 2 diabetes, aggressive 
glycemic control may favorably modify fasting levels of triglycerides and/or HDL 
cholesterol. In patients with impaired fasting glucose who do not have diabetes, a 
lifestyle intervention that includes weight reduction, dietary fat restriction, and 
increased physical activity has been shown to reduce the incidence of type 2 diabetes. 
Metformin also reduces the incidence of diabetes, although the effect is less 
pronounced than that of lifestyle intervention. 
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INSULIN RESISTANCE  
Several drug classes (biguanides, thiazolidinediones [TZDs]) increase insulin 
sensitivity. Because insulin resistance is the primary pathophysiologic mechanism for 
the metabolic syndrome, representative drugs in these classes reduce its prevalence. 
Both metformin and TZDs enhance insulin action in the liver and suppress endogenous 
glucose production. TZDs, but not metformin, also improve insulinmediated glucose 
uptake in muscle and adipose tissue. Benefits of both drugs have been seen in patients 
with nonalcoholic fatty liver disease and polycystic ovary syndrome, and the drugs 
have been shown to reduce markers of inflammation” (10). 
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MATERIALS AND METHODS 
STUDY DESIGN: Cross sectional study 
PERIOD OF STUDY: March 2016 to July 2016(5 months) 
PLACE OF STUDY: Gynaecology OPD, Kilpauk Medical college Hospital, 
Chennai 
SAMPLE SIZE : 118 
 One hundred and eighteen women in reproductive age group, both adolescents 
and adults, attending Gynaecology out-patient clinic at the hospital with menstrual 
irregularity(oligomenorrhea/amenorrhea) or infertility  with or without clinical 
evidence of hyperandrogenism who were diagnosed as having Polycystic ovarian 
syndrome according to Rotterdams criteria were included in the study, after explaining 
the nature of the study and obtaining informed consent for participating in the study. 
 EXCLUSION CRITERIA  
Women with the following factors were excluded from the study 
 1.age >40 years . 
 2. hypothyroidism, hyperprolactinemia 
 3. secondary causes of androgen excess. 
 4.use of oral contraceptive pills in the preceding three months. 
 5. chronic diseases like SLE. 
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 Secondary causes of hyperandrogenism like 21-hydroxylase deficiency, 
Cushing’s syndrome, hypothyroidism, hyperprolactinemia, and androgen secreting 
tumors were excluded by appropriate clinical examination and laboratory tests if 
needed. 
METHOD OF EXAMINATION 
 During clinical examination,. height was recorded to the nearest 0.5 cm and 
weight was taken on a platform type machine, the accuracy of which was checked each 
time before weighing. The weight was recorded in kg with the female wearing minimal 
garments and body mass index(BMI-kg/m2) was calculated in each case form height 
and weight measurements. 
 
The waist circumference was taken with a 1 cm wide inch tape measure in a 
horizontal plane, midway between the inferior margin of the ribs and the superior 
border of the iliac crest.  
 
 A single reading of blood pressure was measured using a standard 
sphygmomanometer after appropriate period of rest, in sitting position.  
 Fasting blood sample of about 6 ml was obtained from the patient for estimation 
of fasting plasma glucose, high density lipoprotein cholesterol(HDL-c) and 
triglycerides levels. Plasma glucose was measured by hexokinase/glucose oxidase 
peroxidase method. HDL-C and triglyceride levels were measured by enzymatic 
colorimetric method by enzymatic colorimetric method. 
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OBSERVATION AND ANALYSIS 
PREVALENCE OF METABOLIC SYNDROME 
 The sample size in our study is 118. Of those, the prevalence of metabolic 
syndrome. 
NO OF PCOS PATIENTS 
STUDIED 
METABOLIC 
SYNDROME 
NO METABOLIC 
SYNDROME 
 118   43(36.4%) 75(63.6%) 
 
   
The above pie diagram represents the prevalence of metabolic syndrome in PCOS 
which is 36.4%. 
 
 
PREVALENCE-36.4%
PCOS WITHOUT METABOLIC
SYNDROME
PCOS WITH METABOLIC
SYNDROME
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PRESENTING COMPLAINTS 
The following are the different complaints for which the PCOS patients came to our 
hospital according to our study. 
 
MENSTRUAL IRREGULARITY 
 
48.3% 
 
PRIMARY INFERTILITY 
 
41.5% 
 
SECONDARY INFERTILITY 
 
8.5% 
 
HIRSUTISM 
 
1.7% 
 
The diagram depicts the different presenting complaints of PCOS, the most common 
PRESENTING  COMPLAINTS
MENSTRUAL IRREGULARITY
PRIMARY INFERTILITY
SECONDARY INFERTILITY
HIRSUTISM
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of which is menstrual irregularity accounting for 48.3% followed by primary infertily 
(41.7%). 
 
AGE DISTRIBUTION OF METABOLIC SYNDROME AMONG PCOS  
Chi square= 9.760         P=0.008 
The above table shows that as age increases, the prevalence percentage of metabolic 
syndrome increases 
 
 
 
AGE GROUP 
 
METABOLIC 
SYNDROME 
 
NO 
METABOLIC 
SYNDROME 
 
TOTAL 
 
UPTO 25 YEARS 
 
12 (25%) 
 
36(75%) 
 
48 
 
26-30 YEARS 
 
18(36%) 
 
32(64%) 
 
50 
 
31 YEARS AND 
ABOVE 
 
 
13(65%) 
 
7(35%) 
 
20 
 
TOTAL 
 
43 
 
75 
 
118 
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BAR CHART DEPICTING THE AGE WISE PREVALENCE PERCENTAGE 
OF METABOLIC SYNDROME 
 
  
The above line diagram shows that the prevalence of metabolic syndrome is in the 
increasing trend with age. 
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ROC CURVE FOR AGE DISTRIBUTION 
 
Area under the ROC curve (AUC)  
   
Area under the ROC curve (AUC)  0.605271 
Standard Errora 0.0597 
95% Confidence intervalb 0.511113 to 0.694014 
z statistic 1.764 
Significance level P (Area=0.5) 0.0778 
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 Sensitivity: 62.8
 Specificity: 62.7
 Criterion : >26
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Even though the prevalence of metabolic syndrome increases with age, the above ROC 
curve shows that age more than 26 is the risk for metabolic syndrome with a sensitivity 
of 62.8% and specificity of 62.7% only. 
 
SOCIOECONOMIC CLASS AND METABOLIC SYNDROME 
 
SOCIOECONOMIC 
CLASS 
 
METABOLIC 
SYNDROME 
 
NO METABOLIC 
SYNDROME 
 
TOTAL 
 
 
CLASS III 
 
11(73.3%) 
 
4(26.7%) 
 
15 
 
CLASS IV 
 
32(31.1%) 
 
71(68.9%) 
 
103 
 
TOTAL 
 
44 
 
74 
 
118 
 
Chi-square= 10.098 P=0.001 
 This table shows that the prevalence of metabolic syndrome is more common in the 
class III socioeconomic status(73.3%) compared to class IV population. The difference 
is statistically significant with P value of 0.001. 
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BMI DISTRIBUTION OF METABOLIC SYNDROME AND NON 
METABOLIC SYNDROME IN PCOS  
 
BMI 
 
 
METABOLIC 
SYNDROME 
 
NO METABOLIC 
SYNDROME 
 
TOTAL 
 
18.5-22.9(normal) 
 
0 
 
37(100%) 
 
37 
23-
24.9(overweight) 
 
5(41.7%) 
 
7(58.3%) 
 
12(100%) 
25-
29.9(preobesity) 
 
16(34.8%) 
 
30(65.2%) 
 
46(100%) 
 
30-39.9(obesity) 
 
19(95%) 
 
1(1.3%) 
 
20(100%) 
40 and 
above(morbid 
obesity) 
3(100%) 0 3(100%) 
TOTAL 43 75 118 
 
Chisquare=56.253    P= ≤ 0.001 
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The above table and bar chart shows that in our study, the prevalence of metabolic 
syndrome increases as BMI increases in the PCOS population. Though the prevalence 
is not much different between over-weight(23-24.9) and pre-obese(25-29.9%), there is 
95% prevalence is obese PCOS(30-39.9) and 100% prevalence is morbidly obese 
PCOS(40 and above). 
 
 
0%
20%
40%
60%
80%
100%
120%
18.5-22.9 23-24.9 25-29.9 30-39.9 40 and
above
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Area under the ROC curve (AUC)  
   
Area under the ROC curve (AUC)  0.894729 
Standard Errora 0.0294 
95% Confidence intervalb 0.824813 to 0.943685 
z statistic 13.440 
Significance level P (Area=0.5) <0.0001 
  
The ROC curve suggests that with increasing BMI, the prevalence of metabolic 
syndrome also increases with a BMI cutoff of  26.56 with 76.7% sensitivity and 90.7% 
specificity.  
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 Criterion : >26.56
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COMPARISON OF PERCENTAGE PREVALENCE OF DIFFERENT 
PARAMETERS OF METABOLIC SYNDROME(between metabolic syndrome 
and non metabolic syndrome) 
 METABOLIC 
SYNDROME(n=43) 
NON METABOLIC 
SYNDROME(n=75) 
Chi-
square 
P 
INCREASED 
WAIST 
CIRCUMFERENCE 
43(100%) 27(36%) 39.424 ≤ 
0.001 
ELEVATED 
SERUM 
TRIGLYCERIDE 
13(30. 2%) 0 25.482 ≤ 
0.001 
LOW SERUM HDL 32(74.4%) 6(8%) 55.223 ≤ 
0.001 
FASTING 
HYPERGLYCEMIA 
26(60.5%) 16(21.3%) 18.256 ≤ 
0.001 
SYSTOLIC 
HYPERTENSION 
18(41.9%) 3(4%) 37.047 ≤ 
0.001 
DIASTOLIC 
HYPERTENSION 
25(58.1%) 6(8%) 55.326 ≤ 
0.001 
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 The above table and bar chart shows the percentage prevalence of each of the 
parameter of metabolic syndrome. Most common parameter altered in metabolic 
syndrome is the low serum HDL(≤50mg/dl) occurring in 74.4% of the metabolic 
syndrome patients, followed by fasting hyperglycemia in 60.5%. 
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MEAN DIFFERENCE OF THE DIFFERENT PARAMETERS BETWEEN 
METABOLIC SYNDROME AND NON METABOLIC SYNDROME GROUP  
WAIST CIRCUMFERENCE 
 
METABOLIC  
SYNDROME N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Mean 
Differn
ence 
P 
WC cm METABOLIC 
SYNDROME 
43 96.84 9.327 1.422  
14.744 
≤ 0.001 
NO 75 82.09 8.398 .970   
  
The mean difference 14.744cm of waist circumference between metabolic syndrome 
and non metabolic syndrome group is statistically significant with a P value of 0.000 
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LIPID PARAMETERS   
 
METABOLIC  
SYNDROME N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Mean 
differenc
e  
P 
S.TGL(mg/dl) METABOLIC 
SYNDROME 
43 124.21 26.628 4.061 15.341 ≤ 0.001 
NO 75 108.87 13.525 1.562   
S.HDL(mg/dl) METABOLIC 
SYNDROME 
43 45.94 5.818 .887 8.873 0.010 
 
NO 75 54.82 4.350 .502   
S.LDL(mg/dl) METABOLIC 
SYNDROME 
43 105.83 20.145 3.072 14.055 ≤ 0.001 
NO 75 91.77 11.049 1.276   
T.CHOL(mg/dl) METABOLIC 
SYNDROME 
43 164.42 27.715 4.226 4.605 0.220 
NO 75 159.81 12.668 1.463   
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The mean difference of S.TGL, S.HDL. S.LDL between metabolic syndrome and non 
metabolic syndrome group is statisticially significant with P VALUE <0.05 except the 
mean difference of S.Total  cholesterol which shows no significant difference. 
 
FASTING BLOOD SUGAR   
 
METABOLIC  
SYNDROME N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
Mean 
Difference 
 
P 
FBS(mg/dl) METABOLIC 
SYNDROME 
43 102.28 18.420 2.809 13.319 
 
≤ 0.001 
NO 75 88.96 13.678 1.579   
 
The mean difference of fasting blood sugar value between metabolic syndrome and 
non metabolic syndrome group is 13.319 which is statistically siginificant with a   P 
value of ≤ 0.001. 
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BLOOD PRESSURE   
 
 
METABOLIC  
SYNDROME N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Mean 
Difference 
P 
BP(mm Hg) Systolic METABOLIC 
SYNDROME 
43 125.63 7.000 1.068 7.788 ≤ 0.001 
NO 75 117.84 9.205 1.063   
BP(mm Hg) Diastolic METABOLIC 
SYNDROME 
43 84.79 6.108 .932 8.711 ≤ 0.001 
NO 75 76.08 7.296 .843   
 
The mean difference of systolic BP and diastolic BP between the metabolic syndrome 
and non metabolic syndrome are 7.788 and 8.711 respectively. Both are statistically 
significant with P value 0.000. 
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AGE, WEIGHT, WAIST CIRCUMFERENCE AND BMI AS  RISK FACTORS 
FOR METABOLIC SYNDROME. 
PARAMETER WITH MS(n=43) WITHOUT 
MS(n 
=75) 
MEAN 
DIFFERERNCE 
P 
AGE  
27.56±4.968 
 
26.31±3.115 
 
1.251 
 
0.095 
WEIGHT  
75.56±13.431 
 
57.33±8.651 
 
18.225 
 
≤ 0.001 
WAIST 
CIRCUMFERENCE 
 
96.84±9.327 
 
82.09±8.398 
 
14.744 
 
≤ 0.001 
BMI  
31.74±5.70 
 
23.90±2.981 
 
7.844 
 
≤ 0.001 
 
The above table shows that age is not a risk factor for metabolic syndrome. The 
difference between metabolic syndrome and non metabolic syndrome group is not 
significant(P=0.095) while weight, waist circumference and BMI are significant risk 
factors. 
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PREVALENCE OF FASTING HYPERGLYCEMIA IN DIFFERENT AGE   
GROUP OF METABOLIC SYNDROME 
AGE GROUP FASTING 
HYPERGLYCEMIA 
TOTAL(n=43) 
UPTO 25 YEARS 4(33.3%) 12 
26-30 YEARS 11(61.1%) 18 
31 YEARS AND ABOVE 11(84.6%) 13 
TOTAL 26 43 
 
Chi-square= 6.870 P=0.032 
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PREVALENCE OF LOW S.HDL IN DIFFERENT BMI GROUPS OF 
METABOLIC SYNDROME 
BMI Low S.HDL TOTAL(n=43) 
18.5-22.9(normal) 0 0 
23-
24.9(overweight) 
1(20%) 5 
25-
29.9(preobesity) 
10(62.5%) 16 
30-39.9(obesity) 18(94.7%) 19 
40 and 
above(morbid 
obesity) 
3(100%) 3 
TOTAL 32(74.4%) 43 
 
Chi-square= 14.123 0.003 
 
The above table shows that low serum HDL level becomes more prevalent as the BMI 
increases in PCOS population (94.7% in obese and 100% in morbidly obese. 
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PREVALENCE OF ACANTHOSIS NIGRICANS IN METABOLIC 
SYNDROME AND NON METABOLIC SYNDROME GROUP 
 ACANTHOSIS NO 
ACANTHOSIS  
TOTAL 
METABOLIC 
SYNDROME 
14(32.6%) 29(67.4%)                                    
43 
NO METABOLIC 
SYNDROME  
3(4%) 
72(96%) 75 
TOTAL 17 101 118 
 
Chi square=18.076        P=≤ 0.001 
The prevalence of acanthosis in metabolic syndrome group is 32.6% while it is only 
4% in those who do not have metabolic syndrome which is significant with a chi square 
value of 18.076 and P value of 0.000. 
 
The bar graph depicts that acanthosis nigricans is more prevalent in the metabolic 
syndrome group(32.6%). 
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PREVALENCE OF HIRSUTISM/HYPERANDROGENISM IN  METABOLIC 
SYNDROME AND NON METABOLIC SYNDROME GROUP 
 HIRSUTISM/HYPERA
NDROGENISM 
NO HIRSUTISM/ 
HYPERANDRO
GENISM  
TOTAL 
METABOLIC 
SYNDROME  
13(30.2%) 30(69.8%) 43 
NO METABOLIC 
SYNDROME  
9(12%) 66(88.8%) 75 
TOTAL 22 96 118 
 
Chi square = 5.990    P = 0.014 
 
 The above table and bar graph show that the prevalence of hirsutism/ 
hyperandrogenism is more in the metabolic syndrome group ie 30.2%  in contrast to 
12 % in the non metabolic syndrome group which is statistically significant with a  P 
value of 0.014. 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
METABOLIC SYNDROME NO METABOLIC SYNDROME
ACANTHOSIS
NO ACANTHOSIS
98 
DISCUSSION 
 The sample size for this study is 118. These are 118 women who are diagnosed 
to have the polycystic ovarian syndrome, but had different presenting complaints. Of 
the 118, the most common problem for which a PCOS woman attending a hospital visit 
is menstrual irregularity according to our study (48.3% had menstrual irregularity 
in terms of oligomenorrhea and amenorrhea as their presenting complaint). 
Primary infertility was the presenting complaint in 41.5 %, 8.5% had secondary 
infertility and 1.7% came for hirsutism.   
Age: 
 The prevalence of  metabolic syndrome in the PCOS study population in this 
study is 36.4%. Age group from 18 to 40 years  were included in the study. The 
prevalence was 25 % in age group less than 25 years, 36% in age from 26 to 30 
years and 65% in age group from 31 years and above. This shows that increase in 
age is an important risk factor for metabolic syndrome in PCOS population. Even 
though the prevalence of metabolic syndrome increases with age, the mean age in 
metabolic syndrome population is 27.56 and the mean age in non – metabolic syndrome 
population is 26.31. 
Socio-economic class: 
 Of the 118 PCOS patients were studied, 14 patients belonged to Class III and 
and 103 belonged to class IV socioeconomic status. Metabolic syndrome was more 
prevalent in the class III socioeconomic PCOS polulation (73.3 % in contrast to 
31.1% in class IV socioeconomic PCOS population). Sedentary life style is the 
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probable  contributory factor in class III population. The difference is statistically 
significant with a P value of 0.001. 
BMI: 
 In our study, the prevalence of metabolic syndrome increases as BMI increases 
in the PCOS population. Though the prevalence is not much different between over-
weight(23-24.9) and pre-obese(25-29.9%), there is 95% prevalence is obese 
PCOS(30-39.9) and 100% prevalence is morbidly obese PCOS(40 and above). 
ANALYSIS OF VARIOUS PARAMETERS OF METABOLIC SYNDROME  
Out of 43 metabolic syndrome patients in PCOS patients 3 parameters were present is 
30(69.7) patients 4 parameters were present in 8(18.6%) patients,  and all 5 parameters 
were present in 2 patients. The most common pattern involved is along with 
increased waist circumference, low serum  HDL and fasting hyperglycemia being 
present in 11 patients amounting to 23.9% and the second most common is increased 
waist circumference along with fasting hyperglycemia and systolic and diastolic 
hypertension being present in 7 patients contributing to 15.2%. 
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Prevalence of metabolic syndrome parameters; 
PARAMETER METABOLIC 
SYNDROME(n=43) 
INCREASED WAIST 
CIRCUMFERENCE 
43(100%) 
ELEVATED SERUM TRIGLYCERIDE 13(30. 2%) 
LOW SERUM HDL 32(74.4%) 
FASTING HYPERGLYCEMIA 26(60.5%) 
SYSTOLIC HYPERTENSION 18(41.9%) 
DIASTOLIC HYPERTENSION 25(58.1%) 
 
WAIST CIRCUMFERENCE 
 Increased waist circumference is the compulsory criteria for diagnosis of 
metabolic syndrome. A waist circumference of 80 cm or above is taken as cut off for 
metabolic syndrome. The mean waist circumference in metabolic syndrome group 
is 96.84 cm and in PCOS population without metabolic syndrome it is 82.09 cm with 
a mean difference of 14.744 and with a standard error of difference of 1.674. Patients 
not falling into the criteria of metabolic syndrome also had a waist circumference of 80 
cm and above. But they didn’t have the other parameters to brand them as metabolic 
syndrome. Thus within the same population, same waist circumference has varied risk 
depending on other parameters. There was no significant difference in the waist 
circumference in different age groups. 
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DYSLIPIDEMIA 
1) SERUM TRIGLYCERIDES 
Triglyceride levels of 150 mg/dl or  above is the cutoff for metabolic 
syndrome. Of the 118 PCOS patients,  10 patients had serum triglyceride value 
of 150 mg/dl or more all had metabolic syndrome. Among 46 patients with 
metabolic syndrome, hypertriglyceridemia was prevalent in 13 patients which 
accounts for 30.2%.  Mean triglyceride value in metabolic syndrome group is 
124.21 mg/dl and in non metabolic syndrome group it is 108.87 mg/dl with a 
mean difference of 15.341, which is statistically significant with a P value of 
0.001. 
 
2) SERUM HDL 
The major lipoprotein disturbance in metabolic syndrome and is low serum 
HDL cholesterol level. The cutoff  for metabolic syndrome is <50 mg/dl. Of the 44 
PCOS patients who had had this value <50 mg/dl, only 31 had metabolic syndrome.  
Among the 46 patients having metabolic syndrome, low levels of serum HDL is 
found in 32 patients(74.4%) becoming the most deranged parameter is PCOS 
women who have MS. The mean HDL value in metabolic syndrome group is 
45.94 mg/dl and in non metabolic syndrome group it is 54.82mg/dl with a mean 
difference of 8.873 which is statistically significant with a P value of 0.010. 
The age prevalence of elevated serum triglycerides low  serum HDL level are 
not different. Though triglyceridemia is equally elevated in all BMI groups, the low 
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S.HDL is significantly high in the obese group with BMI 30-39.9 and morbidly 
obese( BMI 40 and above). 
 
3)FASTING HYPERGLYCEMIA 
Fasting plasma glucose of 100 mg/dl or more is the criteria for MS. 2 patients out 
of the 43 metabolic syndrome patients had fasting hyperglycemia accounding for 
60.5%. Mean fasting glucose value in MS group is 102.28 and in the non MS group it 
is 88.96 with a  mean difference of  13.319 with P value of 0.000 which is statistically 
significant.  
 
HYPERTENSION 
The cutoff for hypertension is 130/85 mm Hg or above. Mean systolic BP in MS 
group is 125.65 mm Hg and in non MS group it is 117.84 mm Hg. with a mean 
difference of 7.778. Mean diastolicBP  in MS group is 84.79 mmHg and in non MS 
group it is 76.08 mm Hg with a mean difference of 8.711. Of the 45 metabolic 
syndrome patients , systolic hypertension was present  in 41.9% and diastolic 
hypertension in 58.1% of patients. 
 
In PCOS patients with metabolic syndrome, the prevalence of fasting 
hyperglycemia increases as age increases, with only 33.3% in age group <25 
years and 66.1% in age 26-30 years and 84.6% in age from 31 years and above. 
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Other parameters does not show statistical difference among different age groups. 
Low serum HDL level becomes more prevalent as the BMI increases in PCOS 
population with metabolic syndrome (94.7% in obese and 100% in morbidly 
obese. Other parameters does not show statistical difference among different BMI 
groups. 
Among other dyslipidemia features, the mean difference of serum LDL between 
metabolic syndrome and non-metabolic syndrome group is statistically significant 
with P value <0.05  but mean difference of S.Total  cholesterol which shows no 
significant difference. 
RISK FACTOR IDENTIFICATION FOR METABOLIC SYNDROME  
 WITH 
MS(n=43) 
WITHOUT 
MS(n 
=75) 
MEAN 
DIFFERERNCE 
P  
AGE 27.56±4.968 26.31±3.115 1.251 0.095 
WEIGHT 75.56±13.431 57.33±8.651 18.225 0.000 
WAIST 
CIRCUMFERENCE 
96.84±9.327 82.09±8.398 14.744 0.000 
BMI 31.74±5.70 23.90±2.981 7.844 0.000 
  
From the above table, by analysis of the mean difference we can say that age is not 
a significant risk factor for metabolic syndrome in PCOS, while weight, waist 
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circumference and BMI are significant risk factors. Metabolic syndrome is prevalent 
in all age groups. 
ACANTHOSIS AND HIRSUTISM/ HYPERANDROGENISM 
 The prevalence of acanthosis in metabolic syndrome group is 32.6% while 
it is only 4% in those who do not have metabolic syndrome which is significant with a 
chi square value of 18.076 and P value of 0.000. 
 The prevalence of hirsutism/ hyperandrogenism is more in the metabolic 
syndrome group ie 30.2%  in contrast to 12 % in the non metabolic syndrome group 
which is statistically significant with a  P value of 0.014. 
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CONCLUSION 
 In recent years India has managed to control the communicable diseases like 
cholera, malaria and polio. Nowadays people in this economically growing world have 
started practicing a sedentary behavior with lack of physical activity. A person who 
lives a sedentary life style is known as “couch potato”. India, being the ‘Diabetes 
capital for the World’, time has come to wage war against obesity and sedentary life 
style related disorders like diabetes and atherosclerotic cardiovascular diseases, as 
diabetes is the major killer disease globally. 
 PCOS being a common condition prevailing in women with reproductive age 
group, is  the cause of problem for one in four patients attending a gynecologist. PCOS 
is a sedentary life and obesity related disorder. Despite treating the infertility and 
menstrual complaints of the PCOS patients, it is a treating doctor’s duty to take it as an 
opportunity to screen for metabolic syndrome and  advice on healthy diet, physical 
activity, weight reduction. Healthy life style modification not only improves their 
menstrual and ovulatory symptoms, but also prevents the future cardiovascular and 
other morbid ailments.   
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STUDY PROFORMA 
 
(PREVALENCE OF METABOLIC SYNDROME IN WOMEN 
WITH POLYCYSTIC OVARIAN SYNDROME  ) 
 
1. Name-       Phone no- 
 
2. Age- 
 
3. Op no- 
 
 
4. Address- 
 
 
5. Socioeconomic status-   
 
                                                                  
6. Menstrual history- 
Age of menarche attainment- 
Regularity of cycle- 
If irregular explain- 
LMP- 
 
 
 
7. Marital history(if applicable)- 
Married since-            years 
Consanguinity- 
 
8. Obstetric history( if  applicable)- 
Parity-       
History of abortion- 
No of living children- 
Last child birth- 
109 
 
 
 
9. Presenting complaint- 
 
10. Features of hyperandrogenism like acne, facial hair etc 
 
11. History of galactorrhea- 
 
12. History of hypo/hyperthyroidism- 
 
 
13. History of SHT/T2 DM/hypercholesterolemia/CKD 
 
 
14. Family history of SHT/T2 DM/hypercholesterolemia 
 
 
15. History of episode of MI/Stroke 
 
16. Other Past history- 
 
h/o TB/ epilepsy/bronchial asthma/drug intake 
 
17. Treatment history- 
 
 
18. Allergy history- 
 
 
 
EXAMINATION 
 
1. Height- 
 
110 
2. Weight- 
 
3. BMI- 
 
4. Waist hip ratio- 
 
5. Blood pressure- 
 
6. Features of hyperandrogenism- 
 
7. Acanthosis nigricans- 
 
8. USG findings- 
 
BLOOD INVESTIGATIONS 
 
1. Fasting blood sugar- 
 
2. Serum triglycerides- 
 
3. Serum HDL- 
 
 
 
 
 
 
SIGNATURE OF THE INVESTIGATOR   SIGNATURE OF THE GUIDE 
 
 
 
 
 
 
 
 
 
NAME AGE age group OPNO SOCIOECO PRESENTI MENSTRU ACANTHO HIRSUTIS HT(cm) Wt(kg) BMI WC(cm) S.TGL(mg/ S.HDL(mg S.LDL(mg/ T.CHOL(m FBS(mg/dl BP(mm Hg)BP(mm Hg)METABO SYOBS SCORE
NIRMALA 18 1 330921 IV MENS IRR YES NO NO 157 93 38.75 102 67 43.4 134 176 63 90 130 1 UNMARRIE
KANIMOZH 19 1 340987 IV MENS IRR YES NO NO 156 92 37.86 101 156 42 108 188 88 90 128 1 UNMARRIE
KALAISELVI 19 1 433398 IV HIRSUTISMYES NO YES 156 90 36.98 102 143 40.1 163 229 88 130 90 1 UNMARRIE
KAVITHA 19 1 321567 IV MENS IRR YES NO YES 156 92 37.86 102 153 40.1 135 217 88 130 90 1 UNMARRIE
MEKALAI 20 1 414123 IV MENS IRR YES NO NO 156 70 28.8 94 126 47 116 167 75 128 76 0 UNMARRIE
SUDHA 21 1 333099 IV MENS IRR YES NO YES 156 84 35.89 99 156 38 120 201 90 90 130 1 UNMARRIE
NATHIYA 21 1 389398 IV MENS IRR YES NO NO 151 75 26.8 92 88 44 97 172 120 80 120 1 UNMARRIE
SHALINI 21 1 409876 III PR INF NO YES NO 150 74 32.8 93 97 40.6 99.2 150 97 90 128 1 NULLIGRV
MATHIARA 21 1 438970 IV MENS IRR YES NO NO 157 62 25.51 79 136 58 107 177 92 128 88 0 UNMARRIE
LATHA 21 1 323232 III MENS IRR YES NO NO 155 64 28.44 89 157 50 102 146 107 110 70 1 UNMARRIE
SAVITHRI 22 1 332120 IV PR INF YES NO NO 154 56 23.62 79 135 56 86 143 76 80 116 0 NULLIGRV
MEENA 22 1 383844 IV MENS IRR YES NO NO 150 45 20 79 110 54 84 156 87 60 100 0 UNMARRIE
SELVI 23 1 221234 IV MENS IRR YES NO NO 150 47 20.88 78 95.5 54 85 154 80 78 126 0 UNMARRIE
SARANYA 23 1 243451 IV MENS IRR YES NO NO 150 58 25.77 78 114 48 103 154 80 78 126 0 UNMARRIE
SOBANA 23 1 345510 IV PR INF YES NO NO 159 56 22.48 77 98.6 58 92 158 71 72 110 0 NULLIGRV
GOMATHI 23 1 399897 IV PR INF YES NO NO 157 56 22.76 77 99 57 87 158 69 72 110 0 NULLIGRV
KARTHIGA 23 1 421098 IV MENS IRR YES NO NO 150 58 25.77 82 108 48 105 154 80 90 126 1 UNMARRIE
PRIYA 23 1 453421 IV PR INF YES NO NO 157 56 22.76 77 99 53 87 158 69 76 110 0 NULLIGRV
ANITHA 23 1 455101 IV PR INF YES NO NO 159 56 22.48 77 98.6 55 92 158 71 70 110 0 NULLIGRV
DEEPA 23 1 400771 IV MENS IRR YES NO NO 150 47 20.88 78 93 58 85 154 80 78 126 0 UNMARRIE
ESHWARI 23 1 454561 IV PR INF YES NO NO 159 56 22.48 77 98.6 57 92 158 71 72 110 0 NULLIGRV
SALIMA 23 1 225643 IV MENS IRR YES NO NO 150 47 20.88 78 93 58 85 154 80 126 78 0 UNMARRIE
CHELLAMA 23 1 309078 IV MENS IRR YES NO NO 150 50 22.2 78 112 54 86 154 74 110 76 0 NULLIGRV
SUMATHI 23 1 243451 IV MENS IRR YES NO NO 150 58 25.77 80 114 48 108 154 80 126 78 0 UNMARRIE
REVATHI 23 1 345510 IV PR INF YES NO NO 157 56 22.76 77 99 58 87 158 69 110 72 0 NULLIGRV
SEEMA 23 1 355101 IV PR INF YES NO NO 159 56 22.48 77 98.6 55 92 158 71 110 72 0 NULLIGRV
THENMOZI 24 1 345512 IV PR INF YES NO NO 157 56 22.76 79 99 58 87 158 69 72 110 0 NULLIGRV
MUMTAZ 24 1 313908 IV PR INF YES NO YES 155 98 40.83 98 144 44 156 216 88 85 120 1 NULLIGRV
GOVINDAM 25 1 351085 IV MENS IRR YES NO NO 150 45 20 79 110 54 84 156 87 60 100 0 P2L2
LAKSHMI 25 1 312908 IV MENS IRR YES NO NO 157 62 25.51 84 136 54.5 104 177 92 88 128 0 UNMARRIE
LAVANYA 25 1 389012 IV MENS IRR YES NO NO 143 50 23.47 73 95 58 84 156 87 60 100 0 P2L2
PRIYA 25 1 400121 IV MENS IRR YES NO NO 159 60 23.8 78 98.6 57 90 155 92 88 128 0 UNMARRIE
POORNIMA 25 1 353561 IV MENS IRR YES NO NO 148 50 22.9 69 95 57 84 156 87 70 100 0 P2L2
GUNAVATH 25 1 333909 IV MENS IRR YES NO NO 156 62 25.51 78 100.4 57 89.5 176 92 88 124 0 UNMARRIE
SUGANYA 25 1 399899 IV MENS IRR YES NO NO 156 62 25.51 78 102.4 56 97 177 93 70 120 0 UNMARRIE
PRATHEEBA 25 1 400987 III MENS IRR YES NO NO 157 62 25.51 79 136 57 110 177 92 80 120 0 UNMARRIE
MALLIGA 25 1 412309 IV MENS IRR YES NO NO 148 50 22.9 87 95 59 84 156 87 60 100 0 P2L2
JANSI 25 1 438970 IV MENS IRR YES NO NO 157 62 25.51 79 136 54.5 87 177 92 88 128 0 UNMARRIE
PORKODI 25 1 351529 IV MENS IRR YES NO NO 150 45 20 79 110 51 84 156 87 60 100 0 P2L2
SUNDARI 25 1 445678 III MENS IRR YES NO NO 157 62 25.51 79 136 52 87 177 92 80 120 0 UNMARRIE
THILAGA 25 1 333908 IV PR INF YES NO NO 157 90 36.43 104 116 43.2 134 197 105 80 120 1 NULLIGRV
KALAIVANI 25 1 345120 IV PR INF YES NO NO 157 56 22.76 79 99 58 95 158 74 110 72 0 NULLIGRV
 JAYANTHI 25 1 333908 IV PR INF YES NO YES 155 92 38.33 110 116 39.6 138 188 105 120 78 0 NULLIGRV
PREMA 25 1 351085 IV MENS IRR YES NO NO 148 50 22.9 69 95 54 84 156 87 100 60 0 P2L2
VANITHA 25 1 335561 IV MENS IRR YES NO YES 157 62 25.51 79 136 58 99.5 177 92 128 88 0 UNMARRIE
DEVI 25 1 351529 IV MENS IRR YES NO NO 150 45 20 79 110 55 84 156 87 100 60 0 P2L2
ARASI 25 1 488129 IV MENS IRR YES NO NO 150 45 20 79 110 54 84 156 87 102 60 0 P2L2
MALAR 26 2 339807 IV PR INF YES NO NO 156 62 25.51 106 118 44 133 187 73 120 90 1 NULLIGRV
KAVITHA 26 2 323289 III MENS IRR YES NO NO 160 64 25 88 107 55 70 146 97 70 110 0 UNMARRIE
VENNILA 26 2 398076 IV MENS IRR YES NO NO 150 47 20.88 76 98 58 86 154 74 76 110 0 NULLIGRV
DIVYA 26 2 331452 IV PR INF YES NO NO 157 68 26.56 94 118 50 110 142 84 80 126 0 NULLIGRV
OORVASI 26 2 309876 IV PR INF YES NO NO 157 68 26.56 90 107 43 113 144 102 80 126 1 NULLIGRV
SASIKALA 26 2 300987 IV MENS IRR YES NO NO 150 50 22.2 82 94 62 86 154 74 76 110 0 NULLIGRV
KOMALA 26 2 400987 IV MENS IRR YES NO NO 150 50 22.2 78 96 54 86 154 74 76 110 0 NULLIGRV
KAMALA 26 2 399543 IV PR INF YES NO NO 156 67 27.57 87 110 59 137 142 90 80 126 0 NULLIGRV
SUMATHI 26 2 391234 IV PR INF YES NO NO 157 68 26.56 87 118 55 90 142 84 80 126 0 NULLIGRV
RANI 26 2 456890 IV PR INF YES NO NO 157 68 26.56 87 118 57 90 142 102 80 126 0 NULLIGRV
BOMMI 26 2 413789 IV PR INF YES NO NO 156 64 26.33 86 133 51 88 156 96 78 118 0 NULLIGRV
ANANDHI 26 2 324292 III MENS IRR YES NO NO 155 64 28.44 110 152 48 91 146 107 74 120 1 UNMARRIE
RADHA 26 2 408971 III MENS IRR YES NO YES 155 64 28.44 103 157 45.4 82 146 107 70 110 1 UNMARRIE
PUNITHAVA 26 2 331452 IV PR INF YES NO NO 157 68 26.56 97 118 57 90 142 102 126 80 0 NULLIGRV
RANJITHAM 26 2 334339 IV PR INF YES NO NO 156 64 26.33 96 103 51 88 156 98 118 78 0 NULLIGRV
EZHIL 27 2 414173 IV MENS IRR YES NO NO 156 70 28.8 104 120 37 116 164 89 76 128 0 UNMARRIE
SEETHA 27 2 303829 IV PR INF YES NO NO 154 56 23.62 75 94 57 88 162 78 80 128 0 NULLIGRV
POONGOD 27 2 345690 IV MENS IRR YES NO NO 156 63 25.92 86 126 52 97 167 75 76 128 0 UNMARRIE
RADHIGA 27 2 421345 IV MENS IRR YES NO NO 156 70 28.8 93 87 41 97 167 75 76 128 0 UNMARRIE
PADHMA 27 2 415609 IV MENS IRR YES NO NO 155 65 27 94 126 54 97 167 75 76 128 0 UNMARRIE
SARASWAT 27 2 400034 III SEC INF NO YES NO 151 85 37.28 101 97 41.4 99.2 150 83 90 130 1 P1L1
MAHALAKS 27 2 441312 III SEC INF NO YES NO 150 86 38.22 103 97 40.6 97 154 83 90 130 1 P1L1
MEENAKSH 27 2 405020 III SEC INF NO NO NO 151 85 37.28 100 86 43.6 102 148 83 90 126 1 P1L1
VENDA 27 2 400043 III SEC INF NO YES YES 151 85 37.28 103 97 42.4 112 143 145 130 90 1 P1L1
DEVIGA 27 2 409876 III SEC INF NO NO NO 150 86 38.22 104 97 40.6 99.2 167 98 120 86 1 P1L1
TAMILARAS 28 2 378965 III PR INF NO NO NO 164 70 26.11 90 122 56 88 158 88 86 126 0 NULLIGRV
KANAGA 28 2 309996 IV PR INF YES NO YES 157 63 25.6 91 103 58 93 144 102 80 126 0 NULLIGRV
MENAGA 28 2 309996 IV PR INF YES NO YES 158 62 24.89 86 104 58 93 144 102 80 126 0 NULLIGRV
NATHIYA 28 2 429271 IV PR INF YES NO YES 157 63 25.6 106 103 53 93 144 88 80 126 0 NULLIGRV
DURGA 28 2 324512 IV PR INF YES YES NO 158 85 34.13 99 100.2 51 128 188 168 85 130 1 NULLIGRV
MOHANA 28 2 409789 III PR INF NO NO NO 164 78 29.1 115 158 57 88 158 88 86 126 1 NULLIGRV
NOORNISH 28 2 378965 III PR INF NO NO NO 164 78 29.1 94 157 44.2 88 158 88 126 86 1 NULLIGRV
MARY 28 2 309721 IV PR INF YES NO YES 157 63 25.6 95 103 48 93 144 102 126 80 1 NULLIGRV
PARVATHY 29 2 401423 IV MENS IRR YES NO NO 155 50 20.8 87 113 56 89 185 115 80 120 0 P2L2
SIVAGAMI 29 2 404078 IV MENS IRR YES NO NO 153 50 21.36 70 89 58 89 178 115 80 120 0 P2L2
THENMOZH 29 2 309867 IV MENS IRR YES NO NO 151 50 21.92 70 93 54.2 89 178 115 80 120 0 P2L2
KUMARI 29 2 331452 IV PR INF YES NO YES 157 68 26.56 87 110 59 90 142 92 80 126 0 NULLIGRV
MALARVIZH 29 2 400912 IV MENS IRR YES NO NO 155 50 20.8 78 113 59 89 185 115 80 120 0 P2L2
VANMATHI 29 2 400818 IV MENS IRR YES YES NO 155 50 20.8 78 113 57 89 185 115 80 120 0 P2L2
MANJULA 29 2 373980 IV SEC INF YES NO NO 154 58 24.47 88 106 44.6 98 167 107 78 106 1 P1L1
VISALATCH 29 2 432098 IV MENS IRR YES NO NO 153 67 28.63 92 133 43.2 99 178 115 80 120 1 P2L2
VENI 29 2 401423 IV MENS IRR YES YES NO 153 50 21.36 70 89 56 89 178 115 120 80 0 P2L2
RAMA 29 2 400912 IV MENS IRR YES NO NO 155 50 20.8 78 113 57 89 185 115 120 80 0 P2L2
NALINI 30 2 398067 IV SEC INF NO YES YES 155 50 20.8 79 92 52 74 167 108 78 120 0 P1L1
TAMILSELV 30 2 373901 IV SEC INF NO NO NO 155 50 20.8 79 110 51 88 167 108 78 120 0 P1L1
VIJAYA 30 2 431897 IV SEC INF NO NO NO 155 50 20.8 79 110 58.5 88 167 108 78 120 0 P1L1
THANGAM 30 2 452134 IV PR INF NO  YES NO 152 62 26.83 86 123 58 83 148 108 90 130 1 NULLIGRV
VIMALA 30 2 412389 IV PR INF NO  NO NO 152 62 26.83 87 118 54 83 148 108 90 130 1 NULLIGRV
BARGAVI 30 2 400912 IV SEC INF NO NO NO 155 50 20.8 79 110 59 88 167 108 120 78 0 P1L1
SAVITHRI 30 2 322290 IV PR INF NO  YES NO 152 62 26.83 89 123 48 83 148 108 130 90 1 NULLIGRV
THAMARAI 31 3 313987 IV PR INF YES YES YES 155 98 40.83 118 158 39 112 189 104 130 90 1 NULLIGRV
RANJANI 31 3 489671 IV PR INF YES YES YES 155 98 40.83 118 158 39 112 189 128 140 80 1 NULLIGRV
SHANTHI 32 3 332121 IV MENS IRR YES NO NO 154 52 21.94 78 123 56 90 146 78 78 120 0 P2L2
BHARATHI 32 3 449099 IV MENS IRR YES NO NO 154 55 23.2 80 123 57 90 146 78 78 120 0 P2L2
BAVANI 32 3 342145 IV PR INF YES  NO YES 156 64 26.33 96 103 51 88 156 98 118 78 0 NULLIGRV
LALITHA 32 3 456999 IV PR INF YES  NO NO 156 80 34.18 96 158 45 102 188 89 80 120 1 NULLIGRV
NAGAMAN 32 3 339090 IV MENS IRR YES NO NO 154 55 23.2 80 123 57 90 146 78 120 78 0 P2L2
SELVI 32 3 342145 IV PR INF YES  NO YES 156 80 34.18 96 165 45 102 188 89 120 80 1 NULLIGRV
KAMATCHI 33 3 336898 IV MENS IRR YES YES NO 156 62 25.51 84 117 54 87 138 107 96 134 1 P2L2
GEETHA 33 3 399977 IV PR INF YES YES NO 154 56 23.62 85 109 60.5 86 143 112 90 134 1 NULLIGRV
SUMADEVI 33 3 424256 IV PR INF YES NO YES 154 56 23.62 81 102 52 86 143 112 80 134 1 NULLIGRV
GANDHIMA 33 3 434871 IV PR INF YES NO NO 154 56 23.62 79 102 57 86 143 112 90 134 1 NULLIGRV
SHANTHA 33 3 334290 IV PR INF YES YES NO 154 56 23.62 79 102 57.5 86 143 112 134 90 1 NULLIGRV
JANAGI 34 3 412345 IV MENS IRR YES NO NO 155 68 27.2 94 99.8 44.8 87 145 109 80 120 1 PILI
SARASU  34 3 449821 IV MENS IRR YES NO NO 155 68 27.2 94 99.8 54 87 145 109 120 80 0 PILI
BALAKUMA 34 3 221119 IV PR INF NO NO YES 157 68 26.56 87 110 59 90 142 92 80 126 0 NULLIGRV
KANNATHA 34 3 467890 IV PR INF NO YES YES 150 82 36.4 98 142 43.2 122 104 118 126 80 1 NULLIGRV
KALIAMMA 35 3 334562 IV HIRSUTISMYES NO NO 154 75 31.64 99 156 41 102 188 96 80 128 1 P2L2
SHYAMALA 38 3 225178 IV PR INF NO YES YES 150 82 36.4 98 142 44 122 104 118 80 126 1 NULLIGRV
MALLIGA 34 3 449121 IV MENS IRR YES NO NO 148 50 22.9 69 95 54 84 156 87 100 60 0 P2L2
JAYA 23 1 33976 IV PR INF YES NO NO 157 90 36.43 104 116 43.2 134 197 105 80 120 1 NULLIGRV
